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1.1 Abstract (English) 
Introduction 
Colorectal cancer (CRC) is one of the most common malignancies worldwide. The role of the 
Hedgehog (Hh) signaling pathway in CRC is controversial. Based on previous data suggesting 
either a paracrine or autocrine tumor-supportive role for Hh, a clinical trial with a specific Hh 
inhibitor was conducted, but yielded a negative result. The aim of this study was to elucidate the 
role of Hh signaling in the development and progression of CRC based on CRC mouse models.  
Methods 
The role of Hh signaling in tumor-stroma crosstalk was analyzed based on chemically induced 
inflammation-driven and sporadic tumor models that were combined with different genetically 
modified mouse strains. By applying immunohistochemistry (IHC) and real-time quantitative 
polymerase chain reaction (RT-qPCR) in combination with Hh reporter mice, we investigated the 
activation of the Hh pathway in murine colonic tumors. Furthermore, we used microarray 
technology for gene expression analysis in mice with genetic activation of the Hh pathway. 
Additionally, we analyzed gene expression data sets of murine or human stromal cells treated with 
Hh ligands in vitro. 
Results 
Hh reporter mice revealed that downstream Hh signaling remains stromal in murine colonic tumors 
and that the canonical Hh pathway is down-regulated during tumorigenesis.  
Transgenic mice with activated Hh signaling in stromal cells showed reduced tumor burden in 
both tumor models. In further support of a protective effect of the Hh pathway in CRC, we found 
down-regulation of the tumor-promoting epithelial transcription factor PROX1 upon genetic Hh 
activation in the stroma.  
Bone morphogenetic protein (BMP) signaling acts as a differentiation factor in the intestinal 
epithelium and is regulated by Hh signaling. Analysis of epithelial p-SMAD1/5 expression, a 
readout of active BMP signaling, revealed an association of Hh activity in the stroma with 
increased BMP pathway activity in the adjacent epithelial compartment. Gene expression data 
suggested that stromal Hh activation diminishes BMP inhibitor expression. Finally, analysis of 
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gene expression in fibroblasts treated with Hh ligand in vitro confirmed down-regulation of BMP 
inhibitor expression upon activation of Hh signaling in intestinal stromal cells. 
Conclusion 
Together, the results suggest a tumor-protective role of stromal Hh activation on CRC formation 
in mice, which may partly be achieved through alterations in the Hh-BMP axis. 
1.2 Zusammenfassung  
Einleitung 
Das kolorektale Karzinom (CRC) ist einer der häufigsten Tumore weltweit. Die Rolle des 
Hedgehog (Hh) Signalweges für die Pathogenese des CRC ist umstritten. Basierend auf früheren 
Daten, welche eine parakrine oder autokrine protumorigene Rolle des Hh Signalweges nahelegten, 
ist eine klinische Studie mit einem spezifischen Hh Inhibitor durchgeführt worden, die jedoch 
keinen positiven Effekt der Hh Inhibition nachweisen konnte. Das Ziel dieser Studie war es daher, 
die Rolle des Hh Signalweges in der Entstehung und Entwicklung vom CRC in Mausmodellen zu 
untersuchen.   
Methodik 
Ein durch die Applikation von chemischen Karzinogenen hervorgerufenes Entzündungs-
abhängiges sowie ein sporadisches CRC Tumormodell wurden in Kombination mit verschiedenen 
transgen veränderten Mausstämmen genutzt, um die Rolle des Hh Signalweges in Wechselspiel 
zwischen Tumor und Stroma zu analysieren. Mit Hilfe von Immunhistochemie (IHC) und 
quantitativer Echtzeit-PCR (RT-qPCR) in Kombination mit Hh Reportermäusen wurde die 
Expression des Hh Signalweges in murinen Kolontumoren untersucht. Für 
Genexpressionsanalysen wurde die Microarray Technologie an Mäusen mit genetisch induzierter 
Hh-Aktivierung angewandt. Zusätzlich wurden Genexpressionsdatensätze, in denen murine und 
humane stromale Zellen in vitro mit Hh Liganden behandelt wurden, hinsichtlich der Expression 
von Hh-regulierten Genen untersucht. 
Ergebnisse 
Wir konnten zeigen, dass die Aktivierung des „kanonischen“ Hh Signalweges in murinen 
Kolontumoren auf das Stroma beschränkt ist und dass Hh Zielgene herunterreguliert sind. Mäuse 
mit Aktivierung von Hh in stromalen Zellen zeigten eine verminderte Tumorlast. Weiterhin 
konnten wir zeigen, dass es nach Aktivierung von Hh zu einer Runterregulierung des 
protumorigenen Transkriptionsfaktors PROX1 kommt. Der „bone morphogenetic protein“ (BMP) 
Signalweg hatte eine pro-differenzierende Rolle im Epithel und wurde durch Hh Signale gesteuert. 
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IHC für p-SMAD1/5, welche die Aktivierung des BMP Signalweges signalisieren, zeigte, dass die 
Aktivität von Hh im Stroma mit erhöhten BMP Signalen im Epithelium einhergeht. In der 
Genexpressionsanalyse zeigte sich, dass stromale Hh Aktivierung die Expression von BMP 
Inhibitoren vermindert, welches sich in der Analyse von Genexpressionsmuster in intestinalen 
Fibroblasten in vitro bestätigte. 
Schlussfolgerung 
Zusammenfassend zeigen unsere Ergebnisse, dass stromale Hh Aktivierung eine protektive Rolle 
auf die Entstehung von CRC in Mausmodellen ausübt, die zumindest in Teilen durch die Hh-BMP 










2.1 Histology of the intestine 
2.1.1 Overview 
The intestine is comprised of the small intestine and the colon, both of which can be further 
subdivided anatomically. Macroscopically, the small intestine consists of three major parts, the 
duodenum, jejunum, and ileum. The large intestine consists of the caecum, colon, and rectum. 
Histologically, the intestinal tract is a three-layered tube 1. Its outer layer, tunica muscularis, 
consists mainly of innervated smooth muscle cells, which orchestrate intestinal peristalsis. The 
middle layer, the submucosa, contains a diverse stromal cell population, vessels and lymphatic 
lacteals 2. The mucosa, the inner layer, consists of the epithelium, the lamina propria, and the 
muscularis mucosae 3. 
The small intestine 
The absorptive surface of the small intestine is significantly increased by projections (villi) and 
invaginations towards the submucosa, termed the crypts of Lieberkühn 1. The small intestinal 
epithelium consists of at least four differentiated cell types: enterocytes, whose main task is 
nutrient absorption; mucus-secreting goblet cells; rare enteroendocrine cells, which produce 
hormones such as serotonin, substance P, and secretin 1; and in the small intestine specifically, an 
additional cell type exists at the bottom of the crypts, called Paneth cells, which produces 
antimicrobial peptides and enzymes such as cryptidins/defensins, and lysozyme, playing a key role 
in innate immunity 1. 
The large intestine  
The main function of the large intestine is the absorption of water and electrolytes. In humans, its 
diameter reaches almost twice that of the small intestine, while it is only one third as long 4. The 
colonic mucosa differs in its composition from the mucosa of the small intestine in that it lacks 
villi and is comprised of crypts only 1. In contrast to the small intestinal epithelium, the large 
intestinal epithelium lacks Paneth cells 5. In addition, the colon contains fewer enteroendocrine 
cells, but more goblet cells. The bottom of the crypt builds a niche for epithelial stem cells 6. 
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2.1.2 The intestinal stroma 
“Stroma” can be defined as the supporting surroundings of an organ, which can be subdivided into 
two major parts: the extracellular matrix (ECM) and the stromal cells 7. The cellular part is 
comprised of pericytes, smooth muscle cells, lymphatic pericytes (colon), smooth muscle cells 
associated with lymphatic lacteals (small intestine), mesenchymal stem cells (MSC), 
myofibroblasts, fibroblasts, and immune cells 8. The histological differentiation of these elements 
is challenging due to the lack of specific markers. Table 1 gives a summary of the major cell types 
of the intestinal stroma and three selected markers used to identify the different components. These 
markers,α-sma, desmin and vimentin, are all intracellular proteins of the cytoskeleton 9. 
Briefly, pericytes (vascular smooth muscle cells) are capillary-associated contractile cells that 
contribute to angiogenesis and revascularization via paracrine signals 9. Smooth muscle cells build 
up the lamina muscularis mucosae and the tunica muscularis, which consists of outer longitudinal 
and inner circular smooth muscle cells 2. MSCs are multipotent cells that can differentiate into 
several different cell types, including osteoblasts, chondrocytes, adipocytes, tenocytes, myocytes, 
and neural cells 11. Fibroblasts, spindle-shaped cells, produce collagens, hyaluronic acid, 
proteoglycans and fibronectins, substances which together form the ECM 12. Myofibroblasts are 
so-called “activated” fibroblasts that express proteins such as α-smooth muscle actin (α-SMA), 
contractile stress fibers and fibronectins 13,14. Myofibroblasts are activated by injury and during 
tumor development, where they adopt a crucial role in the control of epithelial proliferation and 
differentiation processes as outlined below. Furthermore, in conjunction with other stromal cells, 
they contribute to the complex gastrointestinal immune response 9. While the exact origin of 
 α-SMA Desmin Vimentin 
Myofibroblast + - + 
Fibroblast - - + 
Pericyte + +/- + 
Mesenchymal stem cell + - + 
Smooth muscle cell +* + - 
Table 1. Immunhistological markers of stromal cell types. α-SMA = α-smooth muscle actin 
Rows represent cell types, columns represent markers. *negative if precursor cell 10 
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myofibroblasts remains elusive, they have been shown to either stem from resident fibroblasts, 
stellate cells, MSCs, perivascular smooth muscle cells, or through a transdifferentiation process 
called epithelial-to-mesenchymal transition from epithelial cells 9 (outlined in more detail in 
“Charakterisierung des Tumorstromas im Mausmodell kolorektaler Karzinome” Leonard M. 
Kirn, [M23 Hausarbeit, 2015]). 
2.2 Developmental pathways in the intestine 
Interactions of several signaling pathways are pivotal for correct development and homeostasis of 
the intestine. Such developmental pathways consist of a number of successive processes that 
culminate in the expression or repression of specific sets of genes. In the intestine, the three 
morphogenic signaling pathways, Wnt, bone morphogenetic protein (BMP), and Hedgehog (Hh), 
are of central importance. Ligands for each of these pathways are found in specific concentrations 
during development, as well as in the adult intestine in gradients along the crypt(-villous) axis 1 
(Figure 1).  
2.2.1 Wnt signaling  
The Wnt pathway is a main regulator of epithelial proliferation in colonic crypts. Moreover, 
mutations of Wnt pathway members are regularly found in colorectal cancer (CRC) at early stages 
15. Wnt ligands bind to receptors of the “Frizzled” family; upon binding, downstream signals 
inhibit a degradation complex, which consists of the tumor suppressors axin and adenomatous 
polyposis coli (APC). In the absence of Wnt ligands, this complex leads to the degradation of β-
catenin, the major downstream effector of the pathway 16. 
As a result of Wnt activation, β-catenin protein abundance in the cell increases, and it translocates 
into the nucleus to activate several transcription factors of the T cell factor/lymphocyte enhancer 
factor (TCF/LEF) family 5. As the β-catenin/TCF4 complex acts as a main regulator of cell 
proliferation and differentiation, its activation in CRC cells promotes cellular proliferation and 
dedifferentiation 17. The activation of different transcription factors downstream of the Wnt 
pathway in the normal colon differs from that in neoplastic colon cells to some extent, as for 
example the transcription factor prospero homeobox 1 (PROX1), which is thought to promote 
tumor cell growth, is highly expressed in neoplastic cells, but not in the normal intestine 18. 
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2.2.2 Bone morphogenetic protein signaling 
The BMP pathway acts mainly as an antagonist to the Wnt pathway and supports epithelial 
differentiation, while suppressing epithelial proliferation 19. BMPs belong to the transforming 
growth factor-β (TGFβ) superfamily, in which ligands transduce their signals through 
phosphorylation processes of serine-threonine kinase receptors 20. Upon BMP binding to the 
receptor, a receptor-associated Smad (R-SMAD), either SMAD1, -5, or -8, or a combination of 
these gets phosphorylated and builds a complex with SMAD4, the only known “common-partner 
Smad” in mammals 20. Through diverse mechanisms that include direct binding to the DNA, 
interaction with transcription factors, and the recruitment of transcriptional 
coactivators/corepressors, the SMAD dimers regulate the transcription of target genes 20. Activated 
BMP signaling is present in differentiated epithelial cells and in the stroma of the lamina propria, 
signified by the presence of phosphorylated R-SMADs (e.g. by immunohistochemistry for p-
SMAD1/5) 9. 
2.2.3 The Hedgehog pathway 
While Wnt signaling drives intestinal stem cell proliferation and plays an important role in CRC, 
the role of Hh signaling in the intestine is less well defined. There are three active mammalian 
hedgehog proteins: Sonic Hedgehog (SHH), Indian Hedgehog (IHH), and Desert Hedgehog 
(DHH), which all consist of an essential 19-kDa NH2-terminal fragment 
21. The proteins are 
synthesized as 45-kDa precursors, which are highly processed posttranslationally 21. The 
detachment of the lipid-modified Hh proteins from the cell membrane requires the presence of 
Dispatched (DISP) 3. After the release, the Hh ligands bind to Patched (PTCH, of which PTCH1 
and its isoform PTCH2 exist), a 12-transmembrane receptor, which inhibits another seven-
transmembrane protein, smoothened (SMO). The binding of the ligands to PTCH1/2 attenuates 
the inhibitory effect on SMO, which can then activate signaling intracellularly 3. As a result of the 
relief, SMO signals downstream through several kinases, leading to the procession of the three 
glioma-associated protein homologue (GLI) transcription factors: GLI1, GLI2, and GLI3. GLI1 
and GLI2 are mainly processed into activating transcriptional factors, which takes place in the 
primary cilium, a specific cell organelle 22. Target genes of this so-called “canonical” cascade 
include multiple genes such as PTCH1/2, GLI1, and Hedgehog-interacting protein (HHIP), the 
latter of which acts mainly as a negative regulator of the pathway 21. In the intestine, the major Hh 
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ligand is IHH, which is secreted by differentiated enterocytes, while the response is exclusively 
stromal, as evidenced by stromal expression of GLI1 proteins 23.  
The Hh pathway is of major importance for the intestinal development of all bilaterians 21. This is 
confirmed by different mouse models with genetic knockouts in Hh pathway genes, which 
generally results in severe intestinal phenotypes 3. In the adult intestine, Hh signaling is necessary 
for the maintenance of the mesenchymal cells of the lamina propria 3. 
The importance of Hh for mesenchymal homeostasis in the adult intestine was confirmed by 
several experiments designed to alter the level of Hh activity in adult mice. A change in the 
myofibroblast composition was shown, since a body-wide loss of Ptch1 drives myofibroblast 
accumulation 24. Reduction of Hh levels, either by expression of a dominant active form of an Hh 
inhibitor 25 or a specific knockout of Ihh in epithelial cells 26, led to progressive myeloid 
inflammation, loss of differentiated smooth muscle cells and changes in myofibroblast 
composition. A similar study found that decreased Hh signaling is a main cause for a loss of villus 
smooth muscle and the muscularis mucosa 10. Moreover, up-regulation of Hh signaling was found 
to support smooth muscle differentiation 10. These findings implicate that villus smooth muscle 
cells are particularly sensitive to Hh signaling.  
2.3 Cell renewal and stem cells in the intestinal epithelium - complex interactions of 
signaling pathways 
The intestinal epithelium is one of the fastest self-renewing tissues in adult mammals with a 
turnover of 3-5 days 6. The source for this constant epithelial renewal are stem cells located at the 
crypt base, which can be identified by their expression of leucine-rich repeat-containing G- protein 
coupled receptor 5 (Lgr5) 6. These Lgr5+ stem cells in the crypt give rise to transit-amplifying 
cells. While the transit-amplifying cells move up the crypt, they differentiate into the non-dividing, 
terminally differentiated enterocytes and most other cell types of the intestinal epithelial such as 
goblet cells or Paneth cells 27. The major components that build the intestinal stem cell niche are 
neighboring epithelial cells (such as Paneth cells in the small intestine and specific goblet cells in 
the colon 28), mesenchymal cells (intestinal subepithelial myofibroblasts [ISEMFs]), and proteins 
of the basement membrane 29.  
Epithelial Wnt signaling centrally controls the intestinal stem cell state 5. While Paneth cells in the 
crypt bottom were thought to be the main source of Wnt ligands 30, recent data shows that 
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extraepithelial mesenchymal cells also produce Wnt ligands to sustain the intestinal stem cell niche 
31. On the other hand, intestinal differentiation and inhibition of stem cell activation is supported 
by mesenchymally derived BMP signals, which antagonize Wnt signaling, resulting in decreased 
nuclear β-catenin concentrations 9. The pro-differentiating effects of Hh are not yet fully 
understood, but as IHH has been shown to drive stromal BMP synthesis 3, it is generally viewed 
as a negative regulator of epithelial cell proliferation. Consistently, knockout of the main epithelial 
Hh ligand in the adult small intestine leads to an expansion of the intestinal stem cell compartment 
and enterocyte dedifferentiation 26. It has recently been shown that colon crypt myofibroblasts and 
smooth muscle cells secrete BMP antagonists, such as gremlin 1 (GREM1), gremlin 2 (GREM2), 
and chordin-like 1 (CRDL1) to protect the intestinal stem cell niche from differentiation through 
BMPs 32,33. The Wnt, BMP, and Hh pathways are expressed in gradients along the crypt axis 
underscoring their individual role in the balance between colonic proliferation and differentiation 
34 (Figure 1). 
 
Figure 1. Indian Hedgehog, bone morphogenetic protein, Wnt proteins, and bone morphogenetic protein-
antagonist gradient expression in the colonic crypt.  
The main Hh ligand in the colon, IHH, is produced by differentiated epithelial cells, while downstream Hh signal 
transduction is exclusively stromal. Mechanistically, IHH is thought to induce stromal BMP synthesis. BMPs signal 
towards the epithelium, as indicated by phosphorylated Smads (p-SMAD1/5/8). The BMP pathway promotes 
differentiation by inhibiting the Wnt pathway, which itself is up-regulated in the bottom of the crypt, together with 
BMP antagonists that inhibit the effects of BMP signaling, contributing to forming a stem cell niche. 
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2.4 Colorectal cancer 
2.4.1 Epidemiology 
CRC is a pervasive malignant disease: it represents the third most common cancer in men 
worldwide, with 10 % of all new cancer cases in the year 2012, exceeded only by lung (16.7 %) 
and prostate cancer (15.0 %), and the second most common cancer in women with 9.2 % after 
breast cancer, which accounts for 25.2 % 35. CRC causes around 700,000 deaths per year 
worldwide. There are regional differences in incidence with a peak in Australia and New Zealand 
and a minimum in Western Africa 35, which might partly be explained genetically, and partly by 
lifestyle risk factors such as physical inactivity, smoking, obesity, excessive consumption of 
alcohol and red meat 36. While the incidence in Germany has continuously increased since 1980, 
the mortality has declined during the past decades 37. Improved treatment options as well as earlier 
detection through a tailored screening program have contributed to this improvement 38: in 2002, 
a surveillance program was introduced, which includes an annual fecal occult blood test starting 
at the age of 50, and a colonoscopy at the age of 55, followed by defined consecutive surveillance 
intervals. 
2.4.2 Staging and treatment 
CRC diagnosis is mainly established by rectal examination and colonoscopy. Staging of a newly 
diagnosed CRC follows a multidisciplinary approach: in Germany specifically, it includes 
complete colonoscopy, chest radiography, measurement of the tumor marker carcinoembryonic 
antigen (CEA), an abdominal ultrasound, and a physical examination of the patient. Therapeutic 
decisions are generally based on tumor stage, and take into account the individual patient’s 
characteristics. The hallmark of CRC therapy is the surgical tumor removal with total resection 
and lymphadenectomy. The decision about (neo-) adjuvant therapy is based on tumor stage, 
localization, and the individual characteristics of the patient 39. 
2.4.3 Colorectal carcinogenesis and hereditary diseases leading to colorectal cancer 
The adenoma-carcinoma sequence (often referred to as the “Vogelstein model”) describes a model 
of colorectal tumorigenesis in which multiple consecutive somatic mutations lead to progression 
from benign adenomas to carcinomas. Vogelstein et al. distinguished the mutated genes into 
gatekeeper genes, which encode for proteins controlling cell proliferation and differentiation, and 
caretaker genes which, for example, express genome stabilizing products 40. More recently, a new 
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term was coined: landscaper genes; the abnormal expression of these genes does not influence 
cellular growth directly, but results in a pathologic microenvironment, which supports tumor 
growth 41.  
The consecutive mutations in the genes KRAS and APC (examples for gatekeeper genes), tumor 
protein P53 (example for caretaker function), and deleted in colorectal carcinoma (DCC, a 
potential gatekeeper gene 42) all play important roles in tumor development 43. 
The understanding of the underlying pathomechanisms of genetic diseases that increase the risk 
for CRC has shed light on some of the basic principles that drive malignant transformation in the 
colon. Two important hereditary diseases that greatly increase CRC risk are Familial adenomatous 
polyposis (FAP) and hereditary non-polyposis colorectal cancer (HNPCC or Lynch Syndrome). 
Lynch syndrome is an autosomal dominant disease, in which about 90 % of the patients show 
mutations in Mutl-homolog 1 or MutS-homolog 2 genes, and is the most frequent inherited CRC 
syndrome 44. By contrast, FAP patients develop several (>100) colonic adenomatous polyps, which 
entails a 100 % risk of CRC at an average age of 40 if no preventive colectomy is performed 1. 
FAP is caused by a germline mutation in the APC gene, which leads to over activation of Wnt 
signaling 45.  
Recently, a new classification system for CRC has been suggested based on the global gene 
expression patterns of the tumors 46. This system subdivides CRCs into four “consensus molecular 
subtypes (CMS)”: CMS1 (14 %) CRCs are thought to be driven by microsatellite instability and 
BRAF mutations, CMS2 (37 %) cancers show activating mutations in the Wnt- and Myc-signaling 
pathways, CMS3 (13 %) are associated with KRAS mutations and metabolic maladjustments, 
while CMS4 (23 %) tumors depict stromal invasion together with increased angiogenesis, 
probably due to a dysregulation of TGFβ. CRCs of the CMS4 group show the worst overall five-
year survival after diagnosis. 
2.4.4 Histopathology 
The majority (>90 %) of CRCs are adenocarcinomas originating from the epithelial cells of the 
colorectal mucosa 44. By definition, human colorectal adenocarcinomas invade the muscularis 
mucosae into the submucosa 47. Most colorectal adenocarcinomas are gland forming. This feature 
is used as the basis of the histopathologic grading, distinguishing between well- (>95 % gland 
forming), moderately- (50-95 % gland forming) and poorly- (<50 % gland forming) differentiated 
tumors, although grading systems vary among different clinical centers 44. For murine colorectal 
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tumors, the term “intramucosal adenocarcinoma” has been suggested to describe tumors invading 
through the lamina propria into the muscularis mucosae, but not reaching the submucosa 48.  
2.5 The tumor stroma 
The stroma undergoes significant morphological changes during tumor development and 
progression 7. The main phenotype of tumor-associated stromal cells is frequently referred to as 
“cancer-associated fibroblasts” (CAFs), large spindle-shaped cells that comprise a heterogenic 
group of cells, which are present in nearly all solid tumors 49. CRCs are characterized by a 
relatively high abundance of CAFs 50,51 like, for example, breast, prostate and pancreatic cancers 
52, while CAFs are sparse in brain, renal, and ovarian cancers. To date, it has not been possible to 
molecularly define CAFs with specific markers, which highlights their heterogeneity 12. Two main 
markers used to identify CAFs are α-SMA and fibroblast-activation protein α (FAPα), but both 
also mark other cell types and, contrarily, not all CAFs are marked by either α-Sma or FAPα 12. 
The heterogeneity of CAFs makes it challenging to identify their origin (Figure 2). The major cells 
that give rise to CAFs are thought to be resident tissue fibroblasts and MSCs, but an abundance of 
other cell types may contribute 12. 
Among the most important cancer cell-derived factors for the transformation of mesenchymal cells 
into CAFs is TGF-β, which is also the main driver of the activation of fibroblasts towards 
myofibroblasts 53, as well as platelet-derived growth factors, basic fibroblast growth factor, and 
cytokines such as interleukin 6 (IL-6) 12. Functionally, CAFs are thought to influence tumor 
development in diverse ways. First, they contribute to changes in the tumor microenvironment, 
e.g. by the initiation of angiogenesis, the modulation of the tumor metabolism and the immune 
response. Secondly, CAF-derived factors regulate cancer stemness, promote cancer cell migration 
and metastasis, and are involved in the alteration of the therapeutic response by remodeling the 
ECM 12. Figure 2 illustrates the major characteristics of CAFs.  
Data on how the tumor microenvironment in CRC influences cancer development and progression, 
and how it can be used as a prognostic marker, are sparse and controversial. Most data suggest a 
pro-carcinogenic role of the tumor stroma: For example, the tumor microenvironment is 
considered to modulate tumor stemness, i.e. the ability of (undifferentiated) tumor cells to renew 
themselves, by Wnt pathway alterations 33. This seems to be in line with the new CMS which 
describes the CMS4 (mesenchymal) CRCs, defined by high epithelial-to-mesenchymal transition 
activity, high TGFβ signaling, overexpression of ECM proteins, and high levels of angiogenesis, 




Figure 2. The origin of cancer-associated fibroblasts and their roles in carcinogenesis.  
Stromal cells, such as mesenchymal stem cells or resident fibroblasts are reprogrammed by diverse cancer cell-derived 
factors (e.g. TGF-β, platelet-derived growth factor [PDGF], fibroblast growth factor [FGF]). CAFs play different roles 
in cancer development as indicated on the right-hand side. 
2.6 Hedgehog signaling and cancer 
In the majority of human tumors, mutations in Hh-related genes are rare 54. However, specific 
cancer types, such as basal cell carcinoma, medulloblastoma, and rhabdomyosarcoma are driven 
by activating mutations in the Hh pathway 55. In these tumors, Hh acts as a cell-autonomous driver 
of tumorigenesis and downstream signaling is activated, most frequently by deactivating mutations 
in the inhibitory receptor PTCH1 55. This discovery led to the development of Vismodegib, a 
small-molecule inhibitor of SMO, which lies directly downstream of PTCH1 in the signaling 
cascade. Vismodegib is the first approved Hh inhibitor for the treatment of advanced basal cell 
carcinomas 56. 
In CRC, expression of the ligand Sonic hedgehog is up-regulated 57. Moreover, some colon cancer 
cell lines depend on active Hh signaling for proliferation 58. These and other data implied hope for 
a benefit of Hh inhibition with Vismodegib for CRC patients. However, a clinical trial, in which 
Vismodegib was used as an add-on to conventional chemotherapy in patients with metastatic CRC, 
did not demonstrate a positive effect, but rather indicated a trend of lower survival in one study 
arm receiving the Hh antagonist 59. The authors of the trial discussed several possibilities as to 
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why the study failed, such as that potential up-regulation of Hh signaling is not the cause for 
metastatic CRC, or that Vismodegib might interact with the co-therapy 59. 
Another tumor type in which Hh signaling was thought to promote carcinogenesis is pancreatic 
ductal adenocarcinoma (PDAC), which resembles the Hh expression pattern of CRC with an up-
regulation of ligand expression. Similarly to CRC, a clinical study with a different SMO inhibitor 
in patients with PDAC was conducted, which was stopped at interim analysis due to inferior 
outcome in the group that received the inhibitor (http://www.infi.com/ [homepage on the Internet]. 
Infinity Pharmaceuticals, Inc.; [updated Jan. 27, 2012; last accessed 20 June 2016]. URL: 
http://phx.corporate-ir.net/phoenix.zhtml?c=121941&p=irol-
newsArticle_print&ID=1653550&highlight=).  
Recent data provided insight into potential reasons why Hh pathway inhibition in clinic trials lacks 
positive effects: PDAC mouse models treated with IPI-926, another specific SMO inhibitor, 
showed positive effects after a short-term treatment 60, while ongoing inhibition led to decreased 
survival and higher tumor aggressiveness 61. Highlighting the role of Hh in the stroma-tumor 
interaction, deletion of Shh in a PDAC mouse model led to diminished stroma, but also to more 
aggressive tumors with undifferentiated histology and a higher proliferation rate 61. Recent results 
point at a potentially protective effect of Hh activation on PDAC: whereas the genetic and 
pharmacologic inhibition of the Hh pathway results in faster growth of pancreatic neoplasia, 
pathway activation leads to a decrease in proliferation of mutagenic cells 62.  
Complementing the results in PDAC and CRC, a recent publication on bladder cancer provided 
evidence that the Hh pathway has a protective role in tumor progression, partly mediated by 
stromal BMPs 63. 
Taken together, these results question the paradigm of Hh-driven tumor-promoting stroma and 
pose the question of how stromal Hh activation influences CRC development and progression. 
2.7 Mice in (cancer) research  
2.7.1 Colorectal cancer mouse models 
Knowledge of the importance of the Wnt pathway in CRC has been applied to create mouse models 
of intestinal cancer. The ApcMin (Min: multiple intestinal neoplasia) mouse model shows intestinal 
adenoma formation upon a T-to-A transversion in the mouse Apc gene 64, which is largely 
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restricted to the small intestine 65. By contrast, tumors in the colon can be induced with chemical 
carcinogens such as a combination of azoxymethane (AOM) and dextran sodium sulfate (DSS) 66. 
AOM is a carcinogen which induces base mispairings by alkylation of DNA and is activated 
hepatically through a cytochrome P450 dependent process 66. AOM administration leads mainly 
to tumors in the distal part of the colon, corresponding to the most common localization of sporadic 
CRCs in humans 66. Furthermore, tumors occasionally show invasion through the muscularis 
mucosae 67. Also on a molecular level, oncogenic pathways show similarities to human CRC, such 
as up-regulation of Wnt signaling 66. DSS can be used to accelerate tumor development. DSS is a 
pro-inflammatory substance, consisting of a complex glucose polymer. It is administered dissolved 
in the drinking water, consequently harming the epithelium of the murine colon from the luminal 
side and leading to colitis-associated tumors, while the exclusive administration of AOM can be 
regarded as a model for sporadic CRC 66. 
2.7.2 Genetically modified mice with reporter genes  
A reporter gene is an artificially introduced gene used as a readout for the expression of the original 
gene of interest 68. The reporter gene, e.g. the enzyme β galactosidase encoded by the bacterial 
gene LacZ (beta-galactosidase lactose Z), can be integrated into a mammalian gene sequence 
directly downstream of the target gene promoter; cells expressing the gene of interest then also 
express LacZ 69. Using the enzymatic activity of β - galactosidase by exploiting the enzymatic 
reaction of its substrate o-Nitrophenyl- β -D-galactopyranosid into a blue-colored dye serves as a 
readout for transcription of the gene of interest 68. In the case of this study, the Hh downstream 
transcription factor Gli1 served as a target gene, resulting in mice with one wild type (wt) Gli1 





Figure 3.  Reporter mice.  
(a) In Gli1+/lacZ mice the enzymatic activity of beta-galactosidase is used to visualize Gli1 expressing cells. (b) 
Crossing Rosa26-LSL-tdTomato reporter mice with Gli1CreERT2 mice (Gli1CreERT2;Rosa26-LSL-tdTomato)  allows 
visualization of Gli1 expressing cells after tamoxifen induction. (c) Col1a2CreER;R26-LSL-tdTomato reporter mice 
allow visualization of Collagen1a2 (Col1a2) expressing cells after tamoxifen administration. 
2.7.3 Cre-Lox recombination in mice 
The Cre-LoxP system is based on the ability of the enzyme cyclic recombinase (Cre) to delete and 
invert selected DNA sequences. Cre, as a site-specific recombinase, recognizes a specific sequence 
(a 34 base pair recombination target site called “Locus of Crossover in P1” [LoxP]), which can be 
flanked around a gene of interest (then referred to as a “floxed” gene). Cre binds to the first and 
last 13 base pair of the LoxP sequence and catalyzes recombination. When the two LoxP-sequences 
follow the same direction, the embedded DNA is cut out and the resulting circular DNA-fragment 
will be abolished. To invert parts of DNA, antidromic LoxP sides are used 70. To induce 
recombination in adult mice, Cre-proteins with tamoxifen-inducible domains are available (then 
called CreERT) 71.  
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In order to alter Hh activity, for example to achieve Hh activation, loxP sites can be flanked around 
both Ptch1 alleles 72, while the Cre-recombinase is expressed under a fibroblast-specific promoter, 
Collagen1a2 (Col1a2) 73. In Col1a2CreER;Ptch1fl/+ and Col1a2CreER;Ptch1fl/fl mice, tamoxifen 
administration results in Ptch1 knockout mice exclusively in Col1a2 expressing cells, either in a 
single allele (Ptch1fl/+) or homozygous (Ptch1fl/fl) (Figure 4). Recombination can be verified 
indirectly by using a fluorescent protein (e.g. tandem dimer [td]Tomato at the ubiquitous Rosa26 
locus in mice) 74 with a floxed STOP cassette in front as a reporter allele (Figure 3b&c).  
 
Figure 4. Hedgehog activation in mice via the cyclic recombinase-locus of crossover in P1 recombination.  
To achieve Hh activation loxP sites are flanked around both Ptch1 alleles while the Cre-recombinase is expressed 
under Col1a2. In Col1a2CreER;Ptch1fl/+ (a) and Col1a2CreER;Ptch1fl/fl (b) mice, tamoxifen administration results in 
Ptch1 knockout exclusively in Col1a2 expressing cells, either of a single allele (Ptch1fl/+) or homozygously (Ptch1fl/fl). 
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 Research Aims 
Previous studies suggested that the Hh pathway has a tumor-promoting role in CRC, but a clinical 
trial using a pathway inhibitor yielded a negative result. Therefore, the primary aim of this study 
was to investigate the role of Hh for development and progression of CRCs using mouse models. 
3.1 Hedgehog activity in murine colorectal tumors 
While under homeostatic conditions, Hh signals in a paracrine manner in the intestine, it is 
controversial whether the secretion mode in CRC is autocrine 58,75,76 or paracrine 77. The first aim 
of this thesis was therefore to explore if canonical Hh signaling is paracrine or autocrine in murine 
colon tumors. 
3.2 Effect of Hedgehog activation on tumor formation 
Since the use of a specific Hh inhibitor in CRC patients failed in a clinical trial, and Hh-driven 
signals induce epithelial differentiation in non-malignant intestine, the second aim of this thesis 
was to investigate the consequences of Hh activation on tumor development and progression in 
murine colon tumors. For this purpose, a mouse model of stroma-specific Hh activation based on 
the Cre-LoxP recombination system was analyzed. 
3.3 Stromal changes upon Hedgehog activation 
Hh signaling is crucial for the homeostasis of the stroma compartment in the adult intestine. The 
third aim was thus to analyze the cellular changes induced by stromal Hh activation. 
3.4 Crosstalk of Hedgehog and bone morphogenetic protein signaling in colorectal 
cancer  
It has been reported that Hh ligands induce synthesis of stromal BMP agonists. The BMP pathway 
controls cell differentiation in the normal colon as well as in CRC. Hence, the fourth aim of this 
thesis was to specifically investigate changes in the expression of members of the BMP pathway 








Affymetrix Mouse Gene ST 2.0 arrays Santa Clara (California, USA) 
Bright field microscope  Leica DMLB, Leica Microsystems (Wetzlar, 
Germany) 
Centrifuges Eppendorf centrifuge 5417C, Eppendorf AG 
(Hamburg, Germany) 
- Mini Centrifuge C-1200, National Labnet 
Co. (Edison, NJ, USA) 
- Galaxy Mini, VWR International Ltd. 
(Lutterworth, UK) 
- Beckman Coulter Allegra 25 R Centrifuge 
Vortex : Kebo-Lab Reax 2000. KEBO 
Inredningar Sverige AB (Bromma, Sweden) 
 
Charge-coupled device camera  Leica DC 300F 
LSM710 confocal microscope Zeiss (Oberkochen, Germany)  
Pressure cooker 2100 retriever Aptum (Southhampton, United Kingdom) 
VDI 12-homogenisator  VWR International, Radnor (Pennsylvyania, USA) 
Vevo 2100 high-frequency ultrasound system Visualsonics (Toronto, Canada) 
7500 Fast Real-Time PCR system Applied Biosystem (Foster City, California, USA) 
 
4.1.2 Reagents, Materials, and Kits  
Reagents Company 
Alexa Fluor dyes  Invitrogen (Carlsbad, California, USA) 
Alkaline phosphatase-labelled streptavidin  Dako (Glostrup, Denmark)  
Azoxymethane (AOM) Sigma-Aldrich (Saint-Louis, Missouri, USA) 
Avidin DAB plus reagent kit – Invitrogen  
Biotin DAB plus reagent kit – Invitrogen  
Cold fish skin gelatin (CFSG) Sigma-Aldrich 
Corn oil Sigma-Aldrich  
DIVA reagent Biocare Medical (Concard, California, USA) 
Dextran sodium sulfate (DSS) Tdb consultancy (Uppsala, Sweden) 




Ethanol Kemetyl Absolut Finsprit 99,5%, Kemetyl AB, 
(Hanninge, Sweden) 
Fast Red  Dako 
Glutaraldehyde Grade I, 50% in H2O, Sigma-Aldrich 
Hematoxylin stain solution  
 
Sigma-Aldrich 
Hydrogen peroxide Sigma-Aldrich 
Isoflurane Baxter (Deerfield, Illinois, USA) 
Magnesium chloride MIK 0665, Karolinska Substratenheten 
Methanol Sigma-Aldrich 
Mercaptoethanol, >99% Sigma-Aldrich 
Na-Azide Sigma-Aldrich 
N,N,-dimethylformamide Sigma-Aldrich 
Nonidet P-40  BDH Laboratory Supplies (Dubai) 
Paraffin Sigma-Aldrich 
Paraformaldehyde Sigma-Aldrich 
Phosphate buffered saline (PBS) PBS tablets, Medicago 









Power SYBR® green PCR Master Mix containing 
AmpliTaq Gold® DNA Polymerase,  
heat-activated polymerase,  
SYBR® green I Dye,  
buffer components,  
dNTPs, and  
ROX 
Applied Biosystems 




Qiagen (Venlo, Netherlands) 
 
Sodium chloride Sigma-Aldrich 
Streptavidine peroxidase  Invitrogen 
SuperScript ® III First-Strand Synthesis System 
containing: 







SuperScript ® III RT 
oligo deoxythymidylic acid (dT) and 
desoxynucleosid triphosphate (dNTP) mix 
Tamoxifen  Sigma-Aldrich  
Topro-3  Invitrogen 
Tween 80 for molecular biology Sigma-Aldrich 
Triton X-100  Sigma-Aldrich 
Water based mounting medium  Polyscience (Warrington, Pennsylvania, USA) 
X-gal Sigma-Aldrich 
Xylene Sigma-Aldrich 









X-gal substrate solution  stock solution: 100 ml washing buffer, 1 ml 5 mM 
potassium ferricyanide, 1 ml 5 mM potassium 
ferrocyanide, and 2.5 ml 40 mg/ml 5-bromo-4-chloro-
3-indolyl-beta-D-galactopyranoside in N,N,-
dimethylformamide 
Immunofluorescence   blocking solution 5 % BSA in PBS/Tx-100 + 0.01 % Tween 
Immunohistochemistry blocking solution 
 
5% Serum in 1% BSA/PBS, 0.2% CFSG, 0.1% Tx-
100, 0.1% Na-Azide 
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4.1.4 Databases and Software 
Databases/software/plugins Source 
AmiGO2 database v 2.1.4  https://www.geneontology.org (last accessed 2017-04-01) 
Gene expression omnibus (GEO) https://www.ncbi.nlm.nih.gov/geo (last accessed 2017-04-01) 
GraphPad Prism 6.0e software https://www.graphpad.com/, La Jolla, California (last accessed 
2017-04-01) 
GSEA Java plug-in v2.1.0 https://www.software.broadinstitute.org/gsea/index.jsp (last 
accessed 2017-04-01) 
ImageJ´s color deconvolution plug-in  https://imagej.nih.gov/ij/[homepage on the Internet]. ImageJ; color 
deconvolution plug-in; (last accessed 2017-04-01). URL: 
http://www.mecourse.com/landinig/software/cdeconv/cdeconv.html 
Molecular signature data base 
(MSigDB)  
www.broadinstitute.org/gsea/msigdb, Broadinstitut, Cambridge, 
United Kingdom (last accessed 2017-04-01) 
4.2 Mice 
R26-LSL-tdTomato (B6.Cg-Gt[ROSA]26Sortm14[CAG-tdTomato]Hze/J) mice were purchased 
from The Jackson Laboratory (Bar Harbor, ME; Farmington, CT; and Sacramento, CA; all USA); 
Col1a2CreER (B6.Cg-Tg[Col1a2-cre/ERT]7Cpd/J) mice were imported from Benoit de 
Crombrugghe’s laboratory (Houston, Texas, USA); Gli1lacZ/+  (Gli1tm2Alj/J ) and GliCreERT2  mice 
(Gli1tm3(cre/ERT2)Alj/J)  were obtained via the Fritz Aberger laboratory (Salzburg, Austria) and 
originally developed in Alexandra Joyner’s laboratory (see Table 2). C57BL/6J mice were bought 
from Scanbur (Sweden). Ptch1fl/+ mice were developed in the host laboratory and described   
earlier 72. All backcrossings were to C57BL/6J mice. Mice were housed as littermates, separated 
according to sex. In the case of genetically modified Cre-LoxP mice, littermate controls did not 
bear the Cre allele, the floxed alleles or both and were otherwise treated similarly to Cre-LoxP 
mice. 
Ethical approval for animal experiments was obtained from the local ethics committee (permits 
S69/12, S138/12, S10/15, S15/15, and extensions, Jordbruksverket, Sweden). 
We monitored the health status of the mice according to the Karolinska Institute’s scale for the 
assessment of laboratory animals (in a cumulative score including skin condition, movements and 
body posture, piloerection, breathing, excretions, ocular so-called porphyrin production, and food 




4.3 Chemical models of colorectal cancer 
Colonic tumors were induced by giving the mutagenic agent AOM at 12.5 mg/kg body weight 
intraperitoneally (day 0), followed by administration of a 2 % w/v DSS drinking solution for 5 
days starting on day 5 (Figure 5a). Two further DSS cycles were given, interrupted by two weeks 
of regular drinking water. Alternatively, AOM was administered weekly (12.5 mg/kg body weight) 
for ten consecutive weeks, without addition of DSS (Figure 5b).  
Mice Characteristics Reference 
Gli1lacZ/+ Reports Gli1 expression as robust readout of 
active downstream Hh signaling.  
Bai et al. 69 
Gli1CreERT2 Inducible, Cre-driven recombination in cells 
with active downstream Hh signaling (stromal 
cells in case of the intestine) 
Ahn and Joyner 78 
Col1a2CreER Inducible, fibroblast specific transgenic Cre-
driver (targeting a cell population overlapping 
partly with Gli1+ cells) 
Zheng et al. 73 
Ptch1fl/+ 
 
Inducible knockout of one Ptch1 allele to 
activate Hh signaling in the targeted cells 
capable of Hh signaling transduction. 
Kasper et al. 72 
Ptch1fl/fl 
 
Homozygous variant of the above; function as in  
Ptch1fl/+, but stronger activation of Hh signaling 
can be expected. 
Kasper et al. 72 
R26-LSL-
tdTomato 
Reporter mice expressing the fluorescent protein 
tandem dimer [td]Tomato downstream of a 
floxed STOP cassette 
Madisen et al. 74 
Table 2. Mice genotypes and their specific characteristics as used in this thesis. (Hh = Hedgehog, Gli = glioma-





Figure 5. Schematic of azoxymethane/dextran sodium sulfate and azoxymethane treatments.  
(a) AOM/DSS model. Mice received AOM intraperitoneally (day 0), before DSS was given (day 5) orally for 3 cycles, 
with normal drinking water for two weeks in between. (b) AOM model. AOM was given weekly for ten consecutive 
weeks. (AOM = azoxymethane, DSS = dextran sodium sulfate) 
4.4 Tamoxifen treatment 
Mice received 1 mg 4OH-Tamoxifen (diluted in ethanol and corn oil) per 25 g bodyweight 
intrarectally using a plastic gavage tube to limit extracolonic recombination 79.  
In the case of Col1a2CreER or Gli1CreERT2;R26-LSL-Tomato labeling studies, 5 mg tamoxifen 
was injected intraperitoneally at 20 mg/ml, dissolved in corn oil. 
4.5 High-frequency ultrasound 
For quantification of tumor number and size, the Vevo 2100 system high-frequency ultrasound 
system was used, based on a method described previously 80. Briefly, mice were scanned with a 
40 MHz US probe from the rectum rostrally while under anesthesia. The largest tumor diameter 
was identified visually and the tumor border was drawn manually.  
4.6 Immunohistochemistry 
4.6.1 Avidin-biotin complex method  
The avidin-biotin complex method is a routine technique for immunohistochemical (IHC) staining 
based on the high affinity of avidin, a glycoprotein, and strepatavidin (Streptomyces avidinii) to 
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the vitamin biotin. The biotinylated secondary antibody acts as a link between the region of interest 
(antigen), the primary antibody, and an avidin-biotin-peroxidase complex. The peroxidase 
complex enzymatically synthesizes a colored product, which visualizes the expression of the 
protein of interest. 
4.6.2 3,3´-Diaminobenzidine staining  
Four-µm thick paraffin-embedded colon sections were generated by cutting colons longitudinally, 
before being placed in 4 % paraformaldehyde/phosphate buffered saline (PBS) at 4 °C > 8 h for 
fixation. After a 1 h baking step (60 °C) and rehydration, a heat-induced epitope retrieval step with 
DIVA reagent was performed using a pressure cooker. After blocking of endogenous peroxidase 
activity by hydrogen peroxide (3 %), the sections were incubated with diluted primary antibody 
(Table 3) for 1 h (room temperature [RT]) in a moist chamber. Negative controls were performed 
by omitting the primary antibody. The rinsed sections were incubated with biotinylated secondary 
antibody (Table 3; 1:200) for 30 min in the same manner, before streptavidin peroxidase or alkaline 
phosphatase-labelled streptavidin (only β-catenin) administration for 30 min at room temperature. 
For visualization, peroxidase-treated sections were incubated with 3,3´-Diaminobenzidine (DAB) 
or alkaline phosphatase with Fast Red; counterstaining was performed by using hematoxylin or 




Primary Antibody Dilution  Secondary Antibody 
β-catenin (Cell Signaling, Danvers, 
Massachusetts, USA; #9582) 
1:100  Goat anti-rabbit (Vector [Burlingame, 
California]) 
phospho-Smad1/5 (Ser463/465; Cell 
Signaling; 9516S) 
1:50 Goat anti-rabbit (Vector) 
Desmin (Abcam, Cambridge, United 
Kingdom, ab8592) 
1:200 (IF:1:500) Goat anti-rabbit (Vector) 
Vimentin (Santa Cruz, Dallas, 
Texas, USA C20) 
1:200 (IF: 1:500) Rabbit anti-goat (Vector) 
α-Sma (Abcam, ab5694) 1:200 (IF: 1:500) Goat anti-rabbit (Vector) 
anti-collagen1(Abcam, ab34710) IF: 1:200 Goat anti-rabbit (Vector) 
Prox1 (R&D Systems, Minneapolis, 
USA, #AF2727) 
1:200 Rabbit anti-goat (Vector) 
Table 3. Primary antibodies, dilutions, and complementary secondary antibodies.  
4.6.3 X-gal staining 
The staining was done according to Kasper et al. with slight modifications 72. After fixation in 2 
% PFA/PBS with 0.2 % v/v glutaraldehyde for 30 min at room temperature, tissues were washed 
in 2 mM magnesium chloride in PBS plus 0.01 % Nonidet P-40 for 15 min. After a 15 h incubation 
step at 37 °C in X-gal substrate solution (stock solution: 100 ml washing buffer, 1 ml 5 mM 
potassium ferricyanide, 1 ml 5 mM potassium ferrocyanide, and 2.5 ml 40 mg/ml 5-bromo-4-
chloro-3-indolyl-beta-D-galactopyranoside (X-gal) in N,N,-dimethylformamide), the samples 
were washed in PBS and fixed in 4 % PFA/PBS for 4 h at RT before paraffin embedding. 
4.6.4 Quantification of X-gal and DAB staining 
Slides were examined with a standard bright-field microscope and pictures were taken using a 
charge-coupled device camera. The images were used for quantification of DAB and X-gal 
intensities with ImageJ´s color deconvolution plug-in with manual definition of the regions of 




Immunofluorescence (IF) staining was done on frozen sections, cut in 20-100 um thickness. The 
normal serum blocking solution consisted of 5 % BSA in PBS/0.5% Tx-100. The diluted primary 
antibody (Table 3) was incubated overnight immediately after a 30-minute blocking step, before 
washing and incubation of the secondary antibody (in a concentration of 1:250, 45 min, Alexa 
Fluor dyes). Nuclear staining was performed with TOPRO-3 or DAPI 1:1000 in PBS. The results 
were examined using a Zeiss LSM 710 confocal microscope. 
4.7 Real-time quantitative polymerase chain reaction 
Real-time quantitative polymerase chain reaction (RT-qPCR) is an amplification method for 
nucleoid acids allowing the quantification of DNA.  
4.7.1 Purification of ribonucleic acid  
RNA was isolated using the RNeasy midi kit, following the manufacturer’s instructions. The 
principle is based on the selective binding of RNA to a silicon-gel membrane, enriching for 
messenger RNA (mRNA). Twenty -30 mg snap frozen sample was used, either containing tumor 
tissue or normal colon tissue. Immediately prior to RNA extraction, samples were thawed from     
-80 °C.  
Briefly, the frozen tissues were added into 600 l “RLT buffer” (kit reagent) plus 6 l 
mercaptoethanol and homogenized using a VDI 12-homogenisator. Homogenates were then 
centrifuged for 3 min at full speed (14000 x g) and supernatants were discharged before 600 l of 
70 % ethanol was added to the cleared lysate. Up to 700 l of the mixture was transferred to an 
“RNeasy” spin column placed in a 2 ml collection tube and centrifuged for 15 s at 8000 x g. The 
flow through was discarded and the procedure was repeated until no lysate was left. 700 l of 
“RW1 buffer” (kit reagent) were added to the RNeasy spin column and centrifuged again with the 
same settings. 500 l of “RPE buffer” (kit Reagent) were added to the spin column and the sample 
was centrifuged first for 15 s at 8000 x g and after for 2 min at the same speed. 
RNA was subsequently eluted in 30 µl RNA-free water and immediately placed on ice. RNA 
quality and quantity was assessed photometrically. Ratios between 1.8-2.2 (260/280 nm) were 
considered pure 81 and concentrations > 500 ng/l sufficient. 
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4.7.2 First strand complementary deoxyribonucleic acid synthesis 
To synthesize first strand complementary DNA (cDNA) from the purified RNA, the SuperScript ® 
III First-Strand Synthesis System for RT-PCR was used according to the manufacturer’s protocol. 
Briefly, a cDNA synthesis master mix was prepared. For each sample, 4 l 5X RT Buffer, 1 l 0.1 
M DTT, 1 l RNase OUT, and 1 l SuperScript ® III RT (200 U/l) were placed in an autoclaved 
1.5 ml Eppendorf tube. For negative controls SuperScript ® III RT was replaced by RNase-free 
water.  
Next, 1 l 50 μM oligo deoxythymidylic acid (dT), 1 l 10 mM deoxynucleoside triphosphate 
(dNTP) mix, 1 μg total template RNA, and RNase-free water were incubated in a microcentrifuge 
tube at 65 °C for 5 min to denature the RNA before being placed on ice for 1 min. The amount of 
RNase-free water was calculated as shown:  
dH20 = 13 l (total amount)- 1 l 10 mM dNTP mix- 1 l 50 μM oligo(dT) – X l template RNA 
(amount of sample containing 1 μg RNA) 
Subsequently, 7 μl of the cDNA synthesis master mix was added to each RNA mixture. Finally, 
the samples were incubated for 50 min at 50 °C to run the cDNA synthesis, and the reactions were 
terminated by heating to 85 °C for 5 min. 
4.7.3 Real-time quantitative polymerase chain reaction 
We used a SYBR green-based qPCR method. SYBR green is a fluorescent dye, which binds 
double-stranded DNA and increases its signal after binding compared to the unbound dye in free 
solution. The double-strand dye complex absorbs blue light with a wavelength of 488 nm and 
emits green light (522 nm), which can be detected 82. 
As every cycle results in an approximate doubling of the amount of double-stranded DNA in 
optimal conditions, the fluorescence signal will increase exponentially. Real-time PCR was 
performed by using a Power SYBR® green PCR Master Mix, consisting of AmpliTaq Gold® DNA 
Polymerase, heat activated polymerase, SYBR® green I Dye, buffer components, dNTPs, and ROX 
as passive reference dye. A 7500 Fast Real-Time PCR System was used. Master mixes for target 
and housekeeping genes were generated by adding 14 l dH2O, 19 l Fast SYBR green MM, and 
1l 1:5 diluted primer mix (Table 4) per sample-triplicate into an autoclaved Eppendorf tube (1.5 
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ml). The primer dilution consisted of 80 l RNase-free water and of 10l forward- and 10l 
reverse-Primer; RPLP0 and GAPDH were used as housekeeping genes. 
Subsequently, 2 l template DNA was added to each reaction mix aliquote (10 l per well). 
Triplicates were performed as technical repeats. A run consisted of a 10 min heating step and 40 
cycles with each 10 s for denaturation at 95 °C and 30 s at the appropriate annealing temperature 
for annealing and elongation. The delta CT method served to calculate relative mRNA expression, 
and compared the ΔCT values of the samples of interest with control mice samples after 
normalization to the housekeeping genes 83. 
First, we calculated the ΔCT (CT(target)-CT(housekeeping)), before the ΔΔCT (ΔCT (sample of 
interest)-ΔCT (control mice)) was calculated to quantify the relative change in expression between 
two samples (e.g. non-tumor to tumor tissue). Finally, ΔΔCT was converted into the n-fold 
expression: n-fold = 2-ΔΔCt. 





Rplp0/ARP Ribosomal protein, large, P0/ acidic 
ribosomal protein  
forward: GCACTCTCGCTTTCTGGAGGGTGT 
reverse: ATGCAGATGGATCAGCCAGGAAGG 
Gli1 GLI family zinc finger 1 forward: CGTTTAGCAATGCCAGTGACC 
reverse: GAGCGAGCTGGGATCTGTGTAG 
Ihh Indian hedgehog forward: GGCTTCGACTGGGTGTATTA 
reverse: CGGTCCAGGAAAATAAGCAC 
Ptch1 Patched 1 forward: TTGGGATCAAGCTGAGTGCTG,  
reverse: CGAGCATAGCCCTGTGGTTCT 
Shh Sonic hedgehog forward: TGGAAGCAGGTTTCGACTGG 
reverse: GGAAGGTGAGGAAGTCGCTGT 
Gli2 GLI family zinc finger 2 forward: TGAGGAGAGTGTGGAGGCCAGTAGCA 
reverse: CCGGGGCTGGACTGACAAAGC 




Grem1 Gremlin 1 forward: AGACCTGGAGACCCAGAGTA 
reverse: GTGTATGCGGTGCGATTCAT 




Gene product  Full Name Sequence 
Chrdl Chordin-like forward: GATGCTGTTCCCACTGCAC 
reverse: GGCCCATCCTCTTGGTCATA 
Bambi 





Lgr5 Leucine-rich repeat-containing  
G protein-coupled receptor 5 
forward: CCAATGGAATAAAGACGACGGCAACA 
reverse: GGGCCTTCAGGTCTTCCTCAAAGTCA 
Axin2 Axin 2 forward: CAGGAGGATGCTGAAGGCTCAAAGC 
reverse: CTCAAAAACTGCTCCGCAGGCAAAT 
Table 4. Primers for quantitative polymerase chain reduction. (Gli = Glioma-associated protein homologue,  
BMP = Bone morphogenetic protein) 
4.8 Microarrays 
Gene expression microarray analyses allow us to profile gene expression of many different genes 
at the same time and have become a common tool in research 84,85. For microarrays, RNA was 
extracted as described above. Gene expression profiling with RNA of Col1a2CreER;Ptch1fl/fl mice 
and controls was performed using Affymetrix Mouse Gene ST 2.0 arrays in collaboration with the 
Bioinformatics and Expression Analysis core facility at the Karolinska Institute. To assess 
differential expression of preselected gene sets representing defined signaling pathways, we 
applied gene set enrichment analysis (GSEA) 85, using the GSEA Java plug-in v2.1.0 to test non-
log-transformed normalized expression data with standard settings (exceptions: the permutation 
modus was set to “gene_set”, and gene sets <15 genes were accepted). The gene list for BMP 
inhibitors was generated using the AmiGO2 database v 2.1.4 and the list for Hh signaling was 
retrieved from the molecular signature database (MSigDB). 
4.9 Analysis of Gene Expression Omnibus data sets  
Gene Expression Omnibus (GEO) is an online database of the US National Center for 
Biotechnology Information which collects data of gene expression analysis 86. We analyzed two 
different data sets derived from mesenchymal cells treated with Hh ligands in vitro (GSE17840 
and GSE29316) 25,87. The data were accessed using the GEO website. The microarray data were 
normalized with the robust multi-array average (RMA) algorithm using the “affy” package for R 
88 and differential expression between treatment groups was analyzed using limma 89. We selected 
genes of interest (associated to Hh and BMP pathways) and compared differential expression in 
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Hh ligand treated cells compared with vehicle-treated controls. The false discovery rate 
(Benjamini-Hochberg), fdr, was set to <0.05 90.  
4.10 Statistical analyses 
Data analyses (except for microarray and GEO data) were performed using GraphPad Prism 6.0e 
software. Data is presented as the mean and standard error of the means (SEM) unless otherwise 
specified. To compare normally distributed data in two samples, the Student’s t-test was used. The 
type 1-error rate was set to 5 % (*≤ 0.05; **≤ 0.01; ***≤ 0.001). Further specific statistical tests 
are indicated in the text or in the respective figure legends. Bioinformatic programming and 





5.1 Locally advanced tumors upon AOM/DSS treatment 
Many models of intestinal tumors, such as the Apcmin model, are limited to early tumor stages. For 
the AOM/DSS model, invasiveness has been reported, while this feature showed dependence on 
the mouse strain used 91. The earliest invasive tumor, often referred to as “intramucosal 
adenocarcinoma” per definitionem invades into the lamina propria 48. In our case, mice treated 
with AOM/DSS occasionally developed adenocarcinomas that invaded the muscularis mucosae. 
Figure 6 provides representative images of invasive tumors 79. In the example presented in Figure 
6a, the muscularis mucosae is discontinuous, with tumors cells appearing to break through; and in 
the tumor in Figure 6b, neoplastic cells are found below the muscularis mucosae, in parallel to 
tumor-induced changes in the stroma (desmoplasia), as an indirect sign of invasiveness. Yet, due 
to the difficulties to distinguish histologically between invasion and mucosal herniation, which is 
very frequent in mice 67, we did not further quantify invasiveness. Distant metastases were not 
seen on gross macroscopic inspection of the abdominal cavity and the liver.   
 
Figure 6. Histology of invasive AOM/DSS-induced carcinoma, hematoxylin/eosin stained colon sections.   
(a) Invasive tumor. Arrow indicates interrupted muscularis mucosae. (b) Invasive tumor with malignant cells below 
the muscularis mucosae, mucus lakes and desmoplastic stromal reaction (magnification) 79. 
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5.2 Decreased Hedgehog signaling in AOM/DSS-derived colon tumors 
AOM/DSS-induced tumors of Gli1lacZ/+ mice were used to analyze Hh pathway activity in colonic 
tumors, since the lacZ reporter indicates Gli1 transcribing cells that define activated downstream 
Hh signaling. Both macroscopic (Figure 7) and microscopic stainings (Figure 8a&b) indicated 
weaker X-gal-staining in the tumors compared to the adjacent mucosa. 
 
Figure 7. Macroscopic appearance of Gli1lacZ/+ X-gal stained tumors.  
Gli1lacZ/+ mice report downstream Hh expression. Non-malignant mucosa (M) showed strong X-gal staining 





5.3 Hedgehog activity remains stromal and is decreased in tumors 
Histological analysis of whole-mount X-gal stained tissue from Gli1lacZ/+ mice with AOM/DSS-
induced tumors did not reveal epithelial X-gal staining, neither in normal mucosa (Figure 8a), nor 
in tumors (Figure 8b). In both tumors and normal mucosa, Gli1 expression, as visualized by X-gal 
staining, was limited to the stroma (Figure 8). In addition, we found that the tumors showed a 
weaker lacZ signal compared to the adjacent mucosa (Figure 8b), since blue cells appeared largely 
absent in the tumor center 79. 
 
Figure 8. Microscopic appearance of Gli1lacZ/+ X-gal stained colon tissue after azoxymethane/dextran sodium 
sulfate treatment.  
Normal mucosa and an AOM/DSS-induced tumor using X-gal staining to visualize Gli1 expression (a) normal 
mucosa, arrows point at positive X-gal stained cells (blue), which are located in the stroma. (b) AOM/DSS-induced 




5.4 Decreased Hedgehog signaling is paralleled with increased expression of Wnt targets 
To confirm the Hh expression patterns in AOM/DSS-induced tumors on the mRNA level, we used 
RT-qPCR to quantify mRNAs in AOM/DSS-induced tumors and non-malignant mucosa. We 
found that Gli1, Gli2, and Hhip expression, representing Hh target genes, was significantly 
reduced in tumors (Figure 9a, b&c). The mRNA levels of Ptch1 and Ihh (Figure 9f&g) in tumors 
were not significantly different to those in normal mucosa. By contrast, we found the expression 
of canonical targets of Wnt signaling, Lgr5 and Axin2, significantly increased in tumors (Figure 
9d&e) 79.
 
Figure 9. RT-qPCR for Hedgehog and Wnt pathway signals of tumors and matched mucosa.   
Comparison of mRNA expression of Hh (Gli1, Hhip, Ptch1, Ihh) and Wnt (Lgr5, Axin2) pathway members in normal 
mucosa compared to that in tumors relative to the housekeeping gene. Hh signals: (a) Gli; n = 11 (b) Gli2; n = 10 (c) 
Hhip; n = 10 (f) Ihh; n = 11 (g) Ptch1; n = 11. Wnt signals: (d) Lgr5; n = 8 (e) Axin2; n = 9  
(all paired t-tests based on the ∆CT values, *p ≤ 0.05; **p≤ 0.01; ***p ≤ 0.001; multiple test corrected p-values: Gli1: 




5.5 Wnt and Hedgehog pathways are negatively correlated in AOM/DSS tumors  
Because Wnt pathway activation leads to accumulation of β-catenin protein in the nucleus, we 
used IHC against β-catenin as a readout for Wnt activity in tumors of Gli1lacZ/+ mice (Figure 10a). 
In areas of high Wnt activity indicated by nuclear translocation of β-catenin, the stromal X-gal 
signal was reduced, suggesting that Hh signaling is downregulated. Furthermore, we observed that 
Wnt signaling appears to be more active in the tumor center than in its periphery, while X-gal 
staining was stronger in the periphery (Figure 10b) 79. 
 
Figure 10. Immunohistochemistry for β-catenin of X-gal-stained tumors in Gli1lacZ/+ mice.  
(a) IHC for ß-catenin in a X-gal-stained Gli1lacZ/+ tumor, hematoxylin counterstain. Dark blue color indicates positive 
X-gal staining; light blue is hematoxylin counterstain; brown (DAB) shows ß-catenin expressing cells. (b) 
Quantification of the difference in intensity between tumor periphery and center in β-catenin stainings, p = 0.0061 




5.6 Stromal cells with active Hedgehog signaling 
Gli1lacZ/+ mice indicated that downstream Hh activity is limited to certain cells in the colon stroma. 
These results confirmed previous reports that suggested that downstream Hh activation in the 
intestine is restricted to the stroma 23. To independently confirm this finding, we generated a 
different Hh reporter mouse by crossing Rosa26-LSL-tdTomato reporter mice with Gli1CreERT2 
mice (Gli1CreERT2;Rosa26-LSL-tdTomato) (Figure 3). This model allows the visualization of 
Gli1 expressing cells after tamoxifen-induced Cre-mediated recombination in thick frozen sections 
using confocal microscopy 92. To define the Hh target cells in a near-native environment 92, we 
combined confocal detection of tdTomato+ cells with immunofluorescence against the stromal 
markers desmin, vimentin, and α-Sma in whole-mount colon samples from Gli1CreERT2;Rosa26-
LSL-tdTomato mice shortly after tamoxifen induction. These analyses confirmed that Gli1 
expressing cells are located in the colon stroma and not in the epithelium and indicated that they 
comprise a mixed cell population, expressing either one of the three markers or a combination of 
them (Figure 11a,c&e).  
For subsequent experiments, we aimed at activating Hh signaling by knocking out Ptch1 in its 
downstream target cells. However, in Gli1CreERT2 mice, Cre is knocked into the Gli1 locus 69, 
abolishing the function of one Gli1 allele. As this loss of function of Gli1 could influence 
downstream Hh signaling when using Gli1CreERT2 mice to drive Ptch1 knockout, we made use 
of another model, in which Cre expression is driven by a transgenic collagen, type I, alpha 2 
(Col1a2) promoter 73 (Figure 3). IF of Col1a2CreER;R26-LSL-tdTomato reporter mice revealed 
similarities to the Gli1CreERT2 model, as an overlapping stromal cell population expressing all 
three stromal markers was targeted by Col1a2CreER (Figure 11b, d&f). To confirm that 
Col1a2CreER targets a cell population similar to the Gli1CreERT2 model, we stained 
Gli1CreERT2;R26-LSL-dtTomato mice with IF for collagen 1 protein and observed an overlap of 




Figure 11. Confocal images combined with immunofluorescence against the stromal markers α-Sma, desmin 
or vimentin of Gli1CreERT2;Rosa26-LSL-tdTomato and Col1a2CreER;R26-LSL-tdTomato mice.  
Red arrow indicates tomato+ cell, blue arrow indicating either α-Sma+, desmin+ or vimentin+ positive cell; TOPRO-3 
was used as nuclear stain. (a) Gli1CreER; R26-LSL-tdTomato mouse and (b) Col1a2CreER; R26-LSL-tdTomato 
mouse stained for  α -Sma; (c) Gli1CreER; R26-LSL-tdTomato mouse and (d) Col1a2CreER; R26-LSL-tdTomato 
mouse stained for desmin;  (e) Gli1CreER; R26-LSL-tdTomato mouse and (f) Col1a2CreER; R26-LSL-tdTomato 
mouse stained for vimentin;  (g) Gli1CreER; R26-LSL-tdTomato mouse stained for collagen1, yellow indicates 




5.7 Stromal Hedgehog pathway activation attenuates carcinogenesis upon AOM/DSS 
challenge 
As we had shown that Hh activity is downregulated in AOM/DSS-derived colon tumors         
(Figure 8 & Figure 9) in areas of reduced Wnt pathway activity (Figure 10), we were interested in 
how stromal Hh activation would influence colonic carcinogenesis. To this end, we generated 
Col1a2CreER;Ptch1fl/+ mice, which allow activation of Hh signaling exclusively in the stroma 
upon tamoxifen administration (Figure 4).  
5.7.1 Increased Gli1 expression upon stromal loss of one Ptch1 allele  
RT-qPCR analysis of Gli1 mRNA expression showed a trend for an increase in the normal mucosa 
of Col1a2CreER;Ptch1fl/+ mice compared to mucosa of littermate controls, although the difference 
did not reach the level of significance (Figure 12a). As for tumor tissue, Gli1 mRNA expression 
was significantly higher in tumors of Col1a2CreER;Ptch1fl/+ mice  than in tumors of control mice 
(Figure 12b) 79. 
 
Figure 12. Gli1 mRNA expression of Col1a2Cre;Ptch1fl/+ and control mice without stromal Hedgehog activation.  
 (a) Comparison of Gli1 mRNA expression in normal mucosa of control mice and mice with Hh pathway activation. 
p = 0.24; n = 8 control mice and n = 6 Col1a2Cre;Ptch1fl/+ mice. (b) Comparison of Gli1 mRNA expression in tumors 
of control mice with tumors of Col1a2Cre;Ptch1fl/+ mice. p = 0.002; n = 10 control mice and n = 9 Col1a2Cre;Ptch1fl/+ 
mice (for both unpaired t-test of ∆CT values; **p ≤ 0.01). 79 
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5.7.2 Fewer and smaller tumors upon Hedgehog pathway activation  
Upon AOM/DSS challenge, Col1a2CreER;Ptch1fl/+ mice developed significantly fewer tumors 
compared to controls (Figure 13a). Furthermore, tumors in Col1a2CreER;Ptch1fl/+ mice were 
significantly smaller in size than in the control group (Figure 13b) 79. 
 
Figure 13. Tumor number and size of AOM/DSS-treated controls and Col1a2Cre;Ptch1fl/+ mice.  
Comparison of tumor number (a) and size (b) in controls and mice with Hh pathway activation after AOM/DSS 
treatment. (a) Tumor number. Controls (n = 10) and Col1a2Cre;Ptch1fl/+ mice (n = 10); p < 0.0001 (b) Tumor size 




5.8 Decreased PROX1 expression in lesions of Col1a2CreER;Ptch1fl/+ mice 
The transcription factor PROX1 is a Wnt target gene specifically expressed in neoplastic colon 
cells 93. As such, PROX1 expression can be used as a marker for malignant cells with high Wnt 
pathway activity and PROX1 expressing epithelial foci can be seen in dysplastic areas and overt 
tumors. We assessed PROX1 expression with IHC upon Hh activation in tumors and PROX1 
expressing foci of Col1a2CreER;Ptch1fl/+ mice compared to controls. The average PROX1 
intensity per individual lesion was significantly decreased in Col1a2CreER;Ptch1fl/+ mice 
compared to controls (Figure 14). 
 
Figure 14. Prospero homeobox 1 protein expression in mice with Hedgehog activation and control mice. 
(a) Quantification of PROX1 intensity (y-axis, intensity on 8-bit scale) per individual lesion of Col1a2CreER;Ptch1fl/+  
and control mice. p < 0.0001 (unpaired t-test, ***p ≤ 0.001). (b) Representative example of PROX1 IHC of a tumor 
in a control mouse; brown color indicating positive PROX1 staining. (c) Representative example of PROX1 IHC of 
a tumor in a Col1a2CreER;Ptch1fl/+ mouse; brown color indicating positive PROX1 staining, brown color indicating 




5.9 Reduced tumor burden in a sporadic colorectal cancer model in mice with active 
stromal Hedgehog signaling 
To investigate the effect of Hh activation in a model of sporadic colorectal carcinogenesis, we 
used a protocol based on repeated AOM injections without DSS to induce tumors in 
Col1a2CreER;Ptch1fl/+ mice and littermate controls (Neufert 2007). Col1a2CreER;Ptch1fl/+ mice 
challenged with AOM developed fewer tumors and tumors with a significantly smaller volume 
compared to the control group (Figure 15a&b) 79. 
 
Figure 15. Tumor numbers and volumes for azoxymethane treated Col1a2CreER;Ptchfl/+ mice and controls.   
Comparison of tumor number (a) and tumor volume as assessed with 3D ultrasound (b) after AOM treatment in control 
mice and mice with Hh pathway activation. (a) Tumor number. p = 0.143. (b) Tumor volume. p = 0.045 (controls: n 




5.10 P-Smads1/5 expression correlates with Gli1 expression in AOM/DSS-derived 
colorectal cancers  
Since BMP signaling triggers differentiation in colonic stem cells as well as in CRC stem cells, 
and because BMP expression is regulated by Hh signaling 94,95, we sought to investigate if Hh 
pathway activity correlates with downstream activity of the BMP pathway. Protein expression of 
p-SMADs1/5 indicates active BMP signaling. Therefore, we stained tumors in Gli1lacZ/+mice 
immunohistochemically for p-SMADs1/5. IHC for p-SMADs1/5 of tumors induced in Gli1lacZ/+ 
mice showed expression of p-SMADs1/5 that spatially correlated with high Gli1 expression in the 
stroma (Figure 16a). Quantitative analysis confirmed that p-SMADs1/5 immunoreactivity is 
significantly increased at the Gli1-expressing tumor periphery (Figure 16b). 
 
Figure 16. p-Smads 1/5 expression in Gli1lacZ/+ tumors.  
(a) IHC of p-SMADs1/5 in an X-gal-stained Gli1lacZ/+ tumor. Blue color indicates a positive X-gal staining; brown 
color indicates positive DAB staining of p-SMADs1/5 expressing cells. Black arrows indicate positive p-SMADs1/5 
staining’s (brown); red arrows indicate positive X-gal staining (blue), asterisk indicates tumor center, where both p-
SMAD1/5 and X-gal staining was weak to absent. (b) Quantification intensity in tumor periphery and center of p-




5.11  Bmp4 and Bmp5 mRNA expression in AOM/DSS-induced tumors  
Based on the data, supporting an association of the Hh pathway activity and the BMP-p-SMAD1/5 
axis, we sought to confirm our findings by analyzing Bmp4 and Bmp5 mRNA expression in the 
same tumors that were used for the Gli1 mRNA expression analysis. We compared the expression 
patterns of Bmp4 and Bmp5 in tumors and normal mucosa. The analysis of Bmp4 mRNA 
expression in tumors compared to normal mucosa showed a significant up-regulation in the tumors 
(Figure 17a), while Bmp5 expression was not significantly changed (Figure 17b). 
 
Figure 17. RT-qPCR for Bmp4 and Bmp5 mRNA expression of AOM/DSS-induced tumors and matched 
mucosa. Comparison of Bmp4 (a) and Bmp5 (b) mRNA expression in normal mucosa compared to that in AOM/DSS-
induced tumors relative to the housekeeping gene. (a) BMP4 expression (p = 0.0393) (b) BMP5 expression (p = 
0.2323) (both: n = 8 tumors and adjacent mucosa from 8 mice, paired t–test on ∆CT values, *p ≤ 0.05) 
5.12 α-Sma, desmin and vimentin protein expression upon Hedgehog activation 
Since recent publications 96 described changes in the expression of the stroma markers α-Sma and 
desmin upon loss of Hh signaling in the small intestine, we were interested in how Hh activation 
would influence the stromal cell composition as defined by these markers. To this end, we first 
compared the changes following Hh activation in normal mucosa of Col1a2CreER;Ptch1fl/+ mice 
with control mice and subsequently analyzed the changes in tumors of these mice.   
5.12.1 Alteration of vimentin protein expression in normal mucosa upon stromal Hedgehog 
activation 
Neither quantification of α-Sma nor of desmin IHC revealed significant differences between the 
mucosa of Col1a2CreER;Ptch1fl/+ and controls (Figure 18a&b). However, quantification of 
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vimentin indicated a significant downregulation in Col1a2CreER;Ptch1fl/+ mice compared to 
controls (Figure 18c). 
 
Figure 18. Quantification of α-Sma, desmin, and vimentin IHC of control mice mucosa vs. 
Col1a2CreER;Ptch1fl/+ mice mucosa.   
Quantification of the difference in intensity between control mice and Col1a2CreER;Ptch1fl/+ mice mucosa for 
α-Sma: p = 0.5047 (a), desmin: p = 0.6623 (b) and vimentin: p = 0.0061 (c). Y-axis shows the percentage of the stained 
mucosal areas in relation to the overall area covered by the mucosa (all unpaired t-test, **p ≤ 0.01) 
5.12.2 Desmin protein expression in tumors is changed upon stromal Hedgehog activation  
Upon Hh pathway activation in Col1a2CreER;Ptch1fl/+ mice, we detected significant changes 
between the tumor stroma of mice with activated Hh signaling compared to the control group in 
terms of desmin protein abundance (Figure 19c). However, neither α-Sma nor vimentin protein 
expression were significantly different (Figure 19a&b). While the quantification of α-Sma showed 
a trend for up-regulation in tumors with activated Hh signaling compared to the controls, the 
quantification of vimentin showed a non-significant decrease in Hh-activated tumors compared to 




Figure 19. Quantification of α-Sma, vimentin, and desmin stainings of control mice tumors vs. 
Col1a2CreER;Ptch1fl/+ tumors. 
Quantification of the difference in intensity between control mice and Col1a2CreER;Ptch1fl/+ mice tumors for α-Sma: 
p = 0.3287 (a); vimentin: p = 0.4560 (b); and Desmin: p = 0.0014 (c). Y-axis shows the percentage of the stained 




5.13 Reduced expression of Bone morphogenic pathway inhibitors upon Hedgehog 
activation 
In the stroma of Col1a2CreER;Ptch1fl/fl mice (homozygous floxed Ptch1), tamoxifen 
administration leads to “supramaximal” activation of the Hh pathway. We used this model for 
global gene expression analysis with microarray technology and applied GSEA 85 to rank the list 
of differentially expressed genes. The list of genes with the highest scores for down- or up-
regulation after stromal Hh activation confirmed the Hh targets Gli1, Ptch2 and Hhip among the 
top up-regulated genes (Figure 20a). Furthermore, GSEA displayed an enrichment of the canonical 
Hh pathway (gene set derived from MSigDB, gene set name: PID_HEDGEHOG_2PATHWAY) 
in Hh-activated mice versus controls (Figure 20b).  
While stromal Hh activity correlated spatially with epithelial p-SMAD1/5 expression and thus 
with activation of downstream BMP signaling in the epithelium, our data on BMP ligand 
expression (BMP4 and BMP5) was inconclusive. Yet, downstream BMP signaling is modified by 
multiple BMP inhibitors, some of which have been shown to correlate with Hh activity 97. 
Therefore, we were interested in how Hh activation influences BMP inhibitor expression. For this 
purpose, we analyzed the expression of a gene set of BMP inhibitors, including amongst others 
Grem1, Noggin (Nog), Chordin-like (Chrld), and BMP and activin membrane-bound inhibitor 
homolog (Bambi), using GSEA (gene set derived from gene ontology [GO] term “negative 
regulation of BMP signaling pathway"). Interestingly, GSEA revealed downregulation of a set of 




Figure 20. Gene expression microarray analysis of Col1a2CreER;Ptch1fl/fl mice.  
(a) Heatmap of the 8 highest ranked up-regulated genes in Col1a2CreER;Ptch1fl/fl mice (Hh activated) vs. control 
mice. Red color indicates up-regulation and blue color down-regulation of the indicated genes. Hh pathway genes are 
red marked.  
(b) GSEA for the Hh pathway (left) and for BMP inhibitors (right) in Col1a2CreER;Ptch1fl/fl mice (n = 4) vs. controls 
(n = 4). Hh pathway: fdr = 0.001, normalized enrichment score (NES): 2.20, p = 0. BMP inhibitors: fdr = 0.092,  
NES = 1.67, p = 0.0106 79 
5.14 Bone morphogenic protein pathway alterations upon Hedgehog activation in vitro 
Based on the finding that BMP inhibitors are down-regulated upon Hh activation, we sought to 
confirm these results by analyzing if in vitro activation of Hh in stromal cells leads to similar 
expression patterns. We analyzed two GEO data sets (GSE29316 and GSE17840) 25,87, in which 
human colonic fibroblasts were treated with SHH protein, or murine intestinal mesenchymal cells 
with either IHH or SHH N-terminal polypeptide, respectively. In all cases, Hh activation led to 
up-regulation of Gli1/GLI1, confirming activation of downstream Hh signaling (Figure 21). Hh 
activation was paralleled to a significant down-regulation of the BMP inhibitor Grem1/GREM1 
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(Figure 21). While in the cultured intestinal mesenchyme, other BMP inhibitors were not 
significant down-regulated (Figure 21b), and the human colon fibroblast cell line showed a 
significant down-regulation of other BMP inhibitors such as BAMBI, NOG, CHRLD1, and CHRD 
(Figure 21a). 
Since we found activation of downstream BMP signaling upon stromal Hh activity, and our data 
on BMP ligand expression was inconclusive, we revisited BMP ligand mRNA expression upon 
Hh activation in vitro in the public datasets. Again, we found a significant down-regulation of 
BMP4 in the human cell line upon Hh activation (Figure 21a), while the cultured mesenchyme 
showed no significant changes in either Bmp4 or Bmp5 expression (Figure 21b). 
 
Figure 21. Gene expression upon Hedgehog activation in vitro.  
(a) Gene expression of the indicated transcripts in a human colon fibroblast cell line (CCD-18Co) treated with 1μg/ml 
SHH or vehicle for 72 h 87. Red color indicates high expression; blue colour indicates low expression. (b) Gene 
expression of indicated transcripts in cultured intestinal mesenchyme from E18.5 mouse embryos treated either with 




5.15 Bone morphogenetic protein inhibitor down-regulation upon Hedgehog pathway 
activation  
In light of the findings that BMP inhibitors are down-regulated following Hh activation both in 
vivo and in vitro, we sought to validate if the tumors derived from heterozygous 
Col1a2CreER;Ptch1fl/+  mice have a similar pattern of BMP inhibitor expression, which could 
possibly explain the relationship of stromal Hh expression with epithelial BMP induction. To this 
end, we performed RT-qPCRs on tumors of Col1a2CreER;Ptch1fl/+ and control mice for 5 BMP 
inhibitors (Bambi, Chrd, Grem1, Nog and Chrld1) and compared their expression. We found that 
Grem1 was significantly down-regulated (Figure 22). 
 
Figure 22. BMP inhibitor mRNA expression of Hedgehog pathway activated tumors compared to control 
tumors. RT-qPCR was used to assess mRNA expression of BMP inhibitors of tumors derived from 
Col1a2Cre;Ptch1fl/+ mice (light grey) compared to control tumors (dark grey) relative to the HKG.  
(a) Bambi: p = 0.484375. (b) Chrd: p = 0.484375.  (c) Grem1: p = 0.0545.  (d) Nog: p = 0.5823.  (e) Chrld1: p = 
0.484375.  (n = 9 control mice and n = 10 Col1a2Cre;Ptch1fl/+ mice; all unpaired t-tests on ∆CT values with multiple 





6.1 Summary of the results 
In some tumor types, autocrine, cell-autonomous Hh signaling acts as a driver of tumorigenesis. 
The classical example is basal cell carcinoma, which is almost exclusively driven by activation of 
Hh signaling in the tumor cells 55. By contrast, no significant mutations were found in Hh-related 
genes in many other solid malignancies 54. However, based on xenotransplantation studies, 
paracrine Hh signaling (from the tumor cells that produce the ligand to the receiving stroma 
translating the downstream signal) was found to promote tumor growth via microenvironmental 
cues 77. Recently, this view has been challenged by novel animal models that found adverse 
outcomes after Hh inhibition in pancreatic and bladder cancer 62,63,  as well as by clinical trials 
with Hh antagonists in, for example, colon and pancreatic cancer, which yielded no clinical benefit 
59,98. 
Therefore, the present study aimed to elucidate the effect of Hh alterations on CRC development, 
for which controversial data exist. Tumors of two chemically inducible tumor models (AOM/DSS 
or AOM only) for CRC in transgenic mice were analyzed to shed light on the role of Hh signaling 
for tumor-stroma crosstalk.  
Firstly, by analysing mouse models that report Hh activity, we were able to show that Hh activity 
remains stromal and that downstream elements of the Hh pathway are down-regulated in murine 
colon tumors. Immunohistochemically, we found a connection between diminished stromal Gli1 
expression and areas of high Wnt pathway activity in the tumor cells. Moreover, the epithelial 
differentiation markers p-SMADs1/5, were locally enriched in close proximity to stromal cells 
with active Hh signaling, lending support to a pro-differentiating effect of stromal Hh pathway 
activation on the epithelial tumor cells. To explore this hypothesis functionally, we developed a 
mouse model to activate Hh signaling specifically in the stroma, by which we were able to identify 
a protective effect of Hh activation on colorectal carcinogenesis in chemically induced murine 
colonic tumors.  
Gene expression microarray analysis pointed towards altered expression of BMP inhibitors as a 
mediator of this protective effect, an association that we could further confirm for the BMP 
inhibitor Grem1 in vivo. 
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6.2 Advantages and limitations of the study 
6.2.1 The AOM/DSS and the AOM tumor models 
Rodent animal models play an important role in research of intestinal neoplasia and are widely 
used to investigate pathways of tumor development and progression 99. One of their general 
caveats in CRC research is the low frequency of invasiveness, a defining histologic feature of 
CRCs in humans 47. While invasiveness beyond the muscularis mucosae and particularly distant 
metastases are largely absent in the majority of intestinal cancer mouse models, AOM/DSS-
induced tumors do frequently show cytological features of malignancy, then referred to as 
“intramucosal adenocarcinomas”, referring to neoplastic formations of cells that invade into the 
lamina propria or the muscularis mucosae, while the submucosa is not affected 48. To investigate 
human CRCs, the administration of AOM/DSS or AOM to mice is a widely used model 91, as the 
murine CRCs show similarities to their human counterpart, such as their most common 
localization in the distal colon 67, their mutations leading to a Wnt pathway activation (such as Apc 
and Ctnnb1 mutations) 100, and their Kras mutations 101. Our results are consistent with these 
findings as we find activation of the Wnt pathway as indicated by mRNA expression analyses of 
Lgr5 and Axin2 (Figure 9), as well as nuclear translocation of β-catenin by IHC (Figure 10). 
However, it is important to emphasize that, for example, p53 mutations, another hallmark in human 
CRC development, are rarely described in AOM/DSS-induced carcinomas 101,102. 
One advantage of the administration of AOM combined with DSS is that the addition of DSS 
accelerates the growth of colon tumors dramatically compared to the exclusive administration of 
AOM 66. Although the use of DSS can be beneficial for investigating inflammation-driven tumor 
progression (as, for example, ulcerative colitis or Crohn’s disease have been associated with an 
increased risk for CRC 103), the validity of transferring the results to sporadic tumors in patients 
without an inflammatory disease must be critically assessed. Mouse strain-dependent differences 
further complicate the interpretation of the results and their relation to human carcinomas 101. 
Moreover, the murine diet as well as the immunologic status or bacterial colonization of the 
animals influence the metabolism of AOM, which adds another level of complexity when 
comparing results from different laboratories 104.  
A further point to be considered is that the human colon tumors in general are a consequence of 
the exposure to carcinogens over a long period of time, whereas murine tumors arise from a high 




IHC is a well-established technique to assess protein expression in situ 105,106. However, there are 
numerous different antibodies available, which differ in sensitivity and specificity. Regrettably, 
there exists neither a uniform threshold for positivity, nor a standard scoring system 106. To 
quantify our results of DAB and X-gal stainings, we manually defined our regions of interest, 
which is a subjective approach, but cannot be fully avoided due to the nature of IHC 106. 
6.3 Gene expression analysis  
RT-qPCR and gene expression microarrays served to assess the expression levels of the Hh 
pathway, the Wnt pathway and some potentially involved pathways in the stroma-tumor crosstalk 
in tumors and normal mucosa of mice. RT-qPCR is a sensitive technique to analyze mRNA 
expression 107. Optimized primers and reliable housekeeping genes as internal controls are critical 
requirements to gain results of high quality. Housekeeping genes should be expressed 
constitutively in all cells, independently of the experimental setting to be a good internal control 
108. We chose our main housekeeping gene, Rplp0/ARP, an acid ribosomal phosphoprotein, based 
on its characteristic as one of the most reliable housekeeping genes with constant expression levels 
in different cell types 109, as well as based on published data recommending ARP as a housekeeping 
gene especially for use in human bowel-inflammation and cancer research 110. 
While qPCR is restricted to analyze only a handful of genes at a time, microarray analysis allows 
for screening a great number of genes simultaneously 111. When interpreting array results, one 
should be aware that experimental artefacts can occur due to, for example, cross-hybridization 
between probes and the transcripts 112. With the development of GSEA it became possible to assess 
sets of probes for enriched expression regarding, for example, a pathway of interest, hence leveling 
out some of the pitfalls when analyzing single genes 85. 
6.4 The expression pattern of the Hedgehog pathway in the colon 
While autocrine and paracrine Hh activation in CRC have been suggested 75,113, data on the normal 
colon clearly argue for a paracrine signaling mode 3,26,114, from differentiated enterocytes to 
stromal cells, such as smooth muscle cells, myofibroblasts or pericytes 3 (Figure 1). Previously, 
the assessment of Hh expression in situ has been challenging due to the lack of specific antibodies 
for downstream pathway members 77,115. To circumvent this, we took advantage of a β-
galactosidase knock-in to Gli1 in Gli1lacZ/+ mice to visualize Gli1 positive cells. In that way, we 
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were able to confirm a paracrine mode of signaling, as we observed the expression of Gli1, which 
is regarded the most robust indicator of downstream Hh signaling 116, exclusively in the stroma. 
To further assess Hh responsive cell populations, we stained Gli1CreERT2;R26-LSL-Tomato and 
Col1a2CreER;R26-LSL-tdTomato reporter mice for various stromal cell markers. The results 
confirm stromal exclusiveness of downstream Hh activity in the colon and furthermore suggest 
smooth muscle cells, pericytes or fibroblasts as Hh responsive cells (Figure 11). However, it was 
not possible to define a single specific cell population by one stromal cell marker alone as these 
markers are co-expressed by many different cells (Table 1). 
6.5 The role of Hedgehog in chemically induced colorectal tumors 
Previous data suggested a tumor-promoting role of the Hh pathway in human CRC 57,58, which, 
together with a body of in vitro data on Hh expression led to a clinical trial with the Hh inhibitor 
Vismodegib that, regrettably, yielded a negative result 59. Hence, the role of Hh signaling for CRC 
development remained unclear.  
6.5.1 Hedgehog Pathway regulation in AOM/DSS-induced colonic tumors  
The data presented herein are in line with another study that used different mouse models to 
manipulate Hh signaling to reveal a protective effect of stromal Hh signaling on colorectal 
carcinogenesis 117. Together with our data there is strong experimental support that Hh is protective 
in a variety of solid cancers, including pancreatic and bladder cancer 61,62.  
We found down-regulation of stromal Gli1 expression in AOM/DSS-induced tumors using X-gal 
staining of whole-mount samples in Gli1lacZ/+ mice (Figure 7 & Figure 8), which could be 
confirmed on the mRNA level (Figure 9). At the same time, the tumors exhibited up-regulation of 
Axin2, and Lgr5, indicating Wnt pathway activation. The fact that the tumors did not reveal any 
down-regulation in Ptch1 and Ihh mRNA expression (Figure 9 f&g) might be due to the limited 
number of tumors analyzed, or to non-canonical mechanisms involved in the regulation of Hh 
signaling in CRC 118. Mechanisms that could contribute to this effect include the down-regulation 
of the Hh pathway co-receptors CDO, BOC and GAS1 119, as they support the attenuation of the 
inhibitory effect of PTCH1 towards SMO upon Hh ligand binding in the canonical Hh pathway. 
Another explanation as to why Ptch1 might not be down-regulated in tumors could be found in its 
role as a pro-apoptotic receptor in the epithelial compartment 120. Here, bound Hh ligand might 
prevent apoptosis in tumor cells in a non-canonical manner 121. As tumor formation results in the 
disruption of the normal mucosal structure, another reason for the dissociation between Hh ligands 
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and downstream Hh activity could be that the stromal ligand concentration is too low to activate 
downstream Hh signaling. This would be in line with previously published data demonstrating that 
stromal Hh pathway activation is a result of high Hh ligand concentrations at the villus tips, 
generated by folding of the epithelial during intestinal development 122. 
6.5.2 Protective effect of Hedgehog on colorectal carcinogenesis 
To activate the Hh pathway, we made use of Col1a2CreER;Ptch1fl/+ mice, which lose one Ptch1 
allele specifically in Collagen1a2 expressing stroma cells upon tamoxifen administration. In both, 
the inflammation-driven (AOM/DSS) and sporadic (AOM) tumor model, we found a protective 
effect of Hh activation (Figure 13 & Figure 15). These findings support a model, in which stromal 
Hh signals have protective effects in the development of CRC. Furthermore, we were able to show 
that Hh activation leads to down-regulation of the tumor-promoting epithelial transcription factor 
protein PROX1 93 (Figure 14), supporting the hypothesis of a pro-differentiating effect of stromal 
Hh activation. 
The results of Hh down-regulation in colorectal tumors have to be put in context with increased 
Hh pathway activity in adenomas of patients with FAP reported earlier 96. A possible explanation 
is that Hh pathway activity could be necessary for adenoma formation, as it was also shown earlier 
for Apcmin mice 96, but the Hh downstream signal is lost upon further progression to carcinomas. 
This would be in line with the finding that administration of Hh inhibitors to Apcmin mice bearing 
advanced adenomas resulted in bigger adenomas instead of growth restriction 96. Apart from the 
structural and functional differences of these two tissues, such as the presence of villi or the 
existence of Paneth cells in the small intestine, recent data suggest that a higher number of 
oncogenic mutations is needed for tumor development in the murine colon compared to the small 
intestine 123. In addition, Apcmin-driven tumors as well as FAP are based on a single mutation in 
the APC gene, whereas we made use of carcinogen-induced tumors, which are associated with a 
more complex mutation pattern 100,101, and which could explain parts of the differences observed. 
6.6 Changes in stroma composition upon Hedgehog pathway alterations 
The Hh pathway is known to play a crucial role in mesenchymal homeostasis of the adult intestine 
3, and recent data suggest significant changes in the adenoma stroma upon Hh deactivation 124. 
Therefore, we investigated the changes in stromal composition upon Hh activation of normal colon 
mucosa and of the tumor stroma in our mouse model, as potential changes in the tumor stroma 
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could also account for decreased tumor development and progression. Since changes in the stroma 
upon Hh activation occurred in the normal mucosa, we expected similar findings, such as an 
increase of α-Sma positive cells, in the tumors 10. Interestingly, we found a decrease in vimentin 
protein abundance, but no significant changes in the stroma markers α-Sma or desmin in the 
normal mucosa of the Hh-activated Col1a2CreER;Ptch1fl/+ mice compared to control mice.  
A possibility for the limited changes upon the loss of one Ptch1 allele could be that the loss of one 
allele does not result in a sufficiently strong Hh pathway up-regulation to cause fundamental 
changes in the stromal cell composition. Again, it should be emphasized that we analyzed the 
colonic stroma, while Büller et al. focused on the small intestine, which could explain why there 
is a different response upon Hh alterations of the stroma. When looking at the expression of α-
Sma, vimentin, and desmin in tumors with Hh-activated stroma compared to tumors of control 
mice, we found a significant up-regulation of desmin, but no other fibroblast markers. This would 
be in line with Büller et al., who described a loss of desmin and α-Sma positive cells upon the loss 
of Hh signaling 124.  
6.7 The Hedgehog-Bone morphogenetic protein axis: a potential link of the protective 
role of Hedgehog in colorectal carcinogenesis  
Given that Hh signaling activity is decreased in CRC, and stromal Hh activation can act in a 
protective manner on colonic tumor development, we sought to elucidate mechanistic links 
between stromal Hh activation and epithelial differentiation. The BMP pathway has a pro-
differentiating effect on the intestinal epithelium, restrains the stem cell compartment 125 (Figure 
1) and, importantly, is driven by active Hh signaling 3,126. Together with recent investigations by 
Shin et al, which addressed the Hh-BMP axis in bladder cancer, this prompted us to investigate 
the Hh-BMP axis in our study 63.  
Firstly, we were able to identify a correlation between stromal expressed Gli1 and the expression 
of p-SMADs1/5 (Figure 16). As the phosphorylation of SMADs1/5 occurs downstream of Bmp 
ligands, our findings support a model of Ihh-driven stromal Bmp activation 33. Furthermore, as the 
Bmp pathway induces intestinal differentiation and acts as a Wnt pathway antagonist 9, these 
findings support the hypothesis of Hh-BMP-driven tumor suppression. Motivated by these results, 
we sought to confirm the association between the Hh pathway and the BMP-p-SMADs1/5 axis by 
analyzing Bmp4 and Bmp5 mRNA expression in AOM/DSS-induced tumors. While Bmp5 
expression showed a trend for down-regulation in the tumors, the anticipated down-regulation of 
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Bmp4, in accordance to the down-regulation of Gli1, could not be confirmed. Unexpectedly, the 
results even demonstrated an increase of Bmp4 mRNA expression, as it was also reported in 
adenomas of the small intestine 124. It might be possible that Bmp4 and Bmp5 follow different 
regulatory mechanisms during tumor progression. Furthermore, other factors could activate the 
BMP pathway (especially Bmp4) independent of Hh signaling, also in the epithelial cell 
compartment 95.  
To investigate further the mechanisms of how Hh-BMP signaling might restrain colorectal 
carcinogenesis, we analyzed the expression patterns of BMP inhibitors upon Hh activation. BMP 
inhibitors are major stem cell niche factors (Figure 1) and may trigger carcinogenesis in the colon 
34. We found that BMP inhibitor expression is down-regulated upon Hh pathway activation. These 
results further support the hypothesis of a connection between BMP pathway up-regulation (in this 
case via a reduction of BMP suppression), induced by Hh activity. To verify our hypothesis of 
BMP inhibitor down-regulation upon stromal Hh activation, we analyzed two in vitro gene 
expression data sets for the expression of BMP ligands and BMP inhibitors upon stromal Hh 
activation. In both cases, we found significant down-regulation of the BMP inhibitor Grem1 upon 
Hh activation, emphasizing Grem1 as a main factor, associated with tumor growth restriction upon 
Hh activation. Next, we sought to confirm these findings by comparing tumors of 
Col1a2Cre;Ptch1fl/+ mice, which revealed increased Gli1 expression, with tumors of control mice. 
Regarding Hh-activated tumors, we found ambiguous results, as two inhibitors (Nog and Chrld1) 
showed a slight increase, while Bambi, Chrd, and Grem1 indicated decreased expression, which 
might be due to the limited number of tumors analyzed or it could be that not all BMP inhibitors 
have the same impact on tumor formation. Focusing on Grem1, which plays a role for colon tumor 
formation in animal models 34 as well as in human CRC 127,128, our results together with these data 
imply a tumor-protective role of Hh activation via the reduction of BMP inhibitors, especially 




Figure 23. Protective effect of stromal Hedgehog activation on colorectal cancer development.  
In our study, Hh activation in Col1a2Cre;Ptch1fl/+ mice had a protective effect on AOM/DSS-induced CRC 
development. Our results suggest that Hh activation (high Gli1 expression) acts via the Hh-BMP axis, particularly 




 Conclusion and clinical relevance 
Our data are in line with recent publications suggesting a protective effect of Hh signaling in tumor 
growth of different cancer types 61–63. At the same time, they challenge the common model of a 
tumor-promoting role of the stroma, and rather support a protective role, at least inf pancreatic-, 
bladder-, and colorectal cancer. Hh-driven changes emerge as important mediators for these 
protective effects of the stroma. The data furthermore suggest the Hh-BMP axis, via down-
regulation of the BMP inhibitor Grem1, as a potential pathway behind the tumor suppressing 
effects (Figure 23). Further clarification of the role of this stroma-tumor crosstalk in CRC 
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AOM   Azoxymethane 
APC  Adenomatous polyposis coli 
BAMBI  BMP and activin membrane-bound inhibitor homologue 
BMP  Bone Morphogenetic Protein 
CAF  Cancer-associated fibroblast 
cDNA  Complementary DNA 
CEA Carcinoembryonic antigen 
CMS Consensus molecular subtypes 
Chrd   Chordin 
Col1a2  Collagen1a2 
CRC   Colorectal cancer 
CRDL1 Chordin-like 1 
Cre Cyclic recombinase 
CreERT Cre-proteins with tamoxifen-inducible domains 
CSFG Cold fish skin gelatin 
DAB   3,3´-Diaminobenzidine 
DCC  Deleted in colorectal carcinoma  
DHH   Desert Hedgehog 
DISP   Dispatched 
DNA   Deoxyribonucleic Acid 
dNTP  Deoxynucleoside triphosphate 
DSS   Dextran sodium sulfate  
dT   Deoxythymidylic Deoxythymidylic acid 
ECM   Extracellular matrix  
FAP  Familial adenomatous polyposis  
FAPα  Fibroblast-activation protein α 
GEO Gene expression omnibus 
GLI  Glioma-associated protein homologue 
GREM1  Gremlin 1 
GREM2  Gremlin 2 
GSEA  Gene set enrichment analysis 
Hh   Hedgehog 
86 
 
HHIP  Hedgehog-interacting protein 
HNPCC Hereditary nonpolyposis colorectal cancer (or Lynch-Syndrome) 
IF Immunofluorescence 
IHC   Immunohistochemistry 
IHH   Indian Hedgehog 
IL-6   Interleukin 6 
ISEMF Intestinal subepithelial myofibroblast 
LacZ  Gene of the lac operon encoding for beta-galactosidase lactose Z 
LEF Lymphocyte enhancer factor 
Lgr5  Leucine-rich-repeat-containing G protein-coupled receptor 5 
LoxP  Locus of Crossover in P1  
Min Multiple intestinal neoplasia 
mRNA  Messenger Ribonucleic Acid 
MSC Mesenchymal stem cells  
MSigDB Molecular signature data base 
Nog  Noggin 
PBS  Phosphate buffered saline 
PDAC  Pancreatic ductal adenocarcinoma  
PROX1  Prospero homeobox 1 
p-Smad  Phosphorylated-Smad 
PTCH   Patched 
RNA   Ribonucleic acid 
RPLP0/ARP  Ribosomal protein, large, P0/ acidic ribosomal protein 
R-Smad Receptor-associated Smad 
RT-qPCR  Real-time quantitative polymerase chain reaction  
SEM  Standard error of the means  
SHH   Sonic Hedgehog 
Smad  Sma and Mad (Mothers gainst decapentaplegic) 
SMO   Smoothened 
TGF-β  Transforming growth factor-β  
TCF T cell factor 
wt Wild type 
α-SMA  α-smooth muscle actin  
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Gene, protein and mRNA symbols are abbreviated and italicized according to the conventional 
nomenclature 129,130 as follows: 
Species Gene Symbol Protein Symbol mRNA 
Homo Sapiens SHH SHH SHH 
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